The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Biopharmaceutical Contract Manufacturing Market (4th Edition) by Type of Product (API, FDF), Scale of Operations (Preclinical, Clinical and Commercial), Expression System (Mammalian, Microbial and Others), Company Size (Small, Mid-sized, Large and Very Large), Biologics (Antibody, Vaccine, Cell Therapy and Other Biologics) and Key Geographical Regions (North America, Europe, Asia-Pacific, MENA and LATAM)- Industry Trends and Global Forecast to 2030

  • Lowest Price Guaranteed From USD 5,899

  • Published
    February 2021

  • Pages
    783

  • View Count
    27925

Example Insights

Biopharmaceutical-Contract-Manufacturing-Market-Context Biopharmaceutical-Contract-Manufacturing-Market-Example-highlights Biopharmaceutical-Contract-Manufacturing-Market-List Biopharmaceutical-Contract-Manufacturing-Market-Distribution Biopharmaceutical-Contract-Manufacturing-Market-Market-Landscape-of-Emerging-Biologics
Biopharmaceutical-Contract-Manufacturing-Market-Partnerships-and-Collaborations Biopharmaceutical-Contract-Manufacturing-Market-Mergers-and-Acquisitions Biopharmaceutical-Contract-Manufacturing-Market-Recent-Expansions Biopharmaceutical-Contract-Manufacturing-Market-Capacity-Analysis Biopharmaceutical-Contract-Manufacturing-Market-Demand-vs-Supply-Analysis
Biopharmaceutical-Contract-Manufacturing-Market-Big-Pharma-Initiatives Biopharmaceutical-Contract-Manufacturing-Market-Distribution-by-Type-of-Product Biopharmaceutical-Contract-Manufacturing-Market-Attractiveness    

Overview

The development pipelines of big biopharma companies are extensive and it is difficult for such players to carry out manufacturing operations using in house capacities. As a result, such companies often opt to outsource certain aspects of their production processes, predominantly drug substance manufacturing and aseptic filling. Therefore, there is a high demand for contract services from the aforementioned companies

-- Senior Manager Strategic Marketing, a Germany-based Large sized CMO

Over the years, the rising popularity of biologics has led to a paradigm shift in healthcare. In the last decade alone, the annual number of approvals of biopharmaceuticals, by the US FDA, have steadily risen. In fact, in 2019, a total of 28 biopharmaceutical products (including monoclonal antibodies, recombinant proteins and gene therapies) were approved in the US. Further, over 8,000 biological pharmaceutical products are currently under clinical investigation, across the world. Given the evident benefits (including high efficacy, target specificity and favorable safety profiles) of biologics over small molecule drugs, the biopharma market is poised to witness continued and consistent growth over the next several years. However, biologics production is a complex and capital-intensive process fraught with a wide range of challenges. Some of key concerns of contemporary innovators include the rate of attrition of pipeline drugs / therapies, prolonged development timelines, complex molecular structure (which demand niche and specialized expertise), current facility limitations and capacity constraints, and safety and efficacy-related issues.

Given the technical and operational challenges outlined above, an increasing number of drug developers have demonstrated the preference to outsource various parts of their biologics manufacturing operations. The landscape of contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) market, specifically those that claim to have biologics-related capabilities, features a mix of large, mid-sized and small companies. As a result of several mergers and acquisitions, the market is now fairly consolidated with a number of established players operating as one-stop-shops. Moreover, since the biopharmaceutical sector is amongst the most highly regulated industries in the world, biopharma CMOs, specifically those offering regulatory assistance, are perceived as attractive strategic partners (especially to the smaller developer companies). With outsourcing being increasingly accepted as a viable and beneficial business model within the biopharmaceutical industry, we anticipate the biologics manufacturing services market to grow at a steady pace in the coming years.

Scope of the Report

The “Biopharmaceutical Contract Manufacturing Market (4th Edition) by Type of Product (API, FDF), Scale of Operations (Preclinical, Clinical and Commercial), Expression System (Mammalian, Microbial and Others), Company Size (Small, Mid-sized, Large and Very Large), Biologics (Antibody, Vaccine, Cell Therapy and Other Biologics) and Key Geographical Regions (North America, Europe, Asia-Pacific, MENA and LATAM)- Industry Trends and Global Forecast to 2030” report features an extensive study on the contract service providers within the biopharmaceutical industry. The study features in-depth analyses, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and contract development and manufacturing organizations (CDMOs). Amongst other elements, the report includes:

  • A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring an elaborate list of active CMOs, along with information on a number of relevant parameters, such as year of establishment, company size, location of headquarters, types of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), scale of operation (preclinical, clinical and commercial), types of expression systems used (mammalian, microbial and others), type of bioreactor used (single-use bioreactors and stainless steel bioreactors), mode of operation of bioreactors (batch, fed-batch and perfusion), bioprocessing capacity and type of packaging. 
  • A detailed landscape of the biopharmaceutical manufacturing facilities established across the key geographical regions (North America, Europe, Asia-Pacific and Rest of the World), and including an analysis based on the location of these facilities, highlighting key manufacturing hubs for biologics.  
  • Elaborate profiles of key players that claim to have a diverse range of capabilities related to the development, manufacturing and packaging of biologics. Each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), as well as an informed future outlook. 
  • A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.
  • A case study on the growing global biosimilars market, highlighting the associated opportunities for biopharmaceutical CMOs and CDMOs. 
  • A case study comparing the key characteristics of small and large molecule drugs, along with details on the various steps involved in their respective manufacturing processes. 
  • A detailed discussion on the benefits and challenges associated with in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource the production operations.
  • A qualitative analysis, highlighting the various factors that need to be taken into consideration by biopharmaceutical therapeutics / drug developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
  • A review of the various biopharmaceutical based manufacturing initiatives undertaken by big pharma players (shortlisted on the basis of the revenues generated by the top 10 pharmaceutical companies in 2019), highlighting trends across various parameters, such as number of initiatives, year of initiative, purpose of initiative, type of initiative, scale of operation, types of biologics manufactured and type of product.
  • An analysis of the recent collaborations (signed since 2015) focused on the contract manufacturing of biologics, based on various parameters, such as the year the agreement was signed, type of agreement, focus area, types of biologics manufactured, therapeutic area and geographical regions. 
  • A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired during 2015-2020, along with the geographical distribution of this activity. The analysis also depicts the relationship between important deal multiples (based on revenues), number of employees and experience of the acquired company. 
  • A detailed analysis of the recent expansions undertaken (since 2015) by various service providers for augmenting their respective biopharma contract manufacturing service portfolios, based on a number of parameters, including year of expansion, purpose of expansion (capacity expansion and new facility), types of biologics manufactured, geographical location of facility, and most active players (in terms of number of instances).
  • An analysis of the recent developments within the biopharmaceutical contract manufacturing industry, highlighting information on the funding and technology advancements related to biomanufacturing. 
  • A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders (small, mid-sized, large and very large CMOs / CDMOs) engaged in the market, using data from both secondary and primary research. The study examines the distribution of global biopharmaceutical manufacturing capacity by scale of operation (preclinical / clinical, commercial), company size (small, mid-sized, large and very large), and geography (North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia-Pacific (China, India, Japan, South Korea and Australia), Latin America, Middle East and North Africa). 
  • An informed estimate of the annual demand for biologics, taking into account the top 25 biologics, based on various relevant parameters, such as target patient population, dosing frequency and dose strength of the abovementioned products.
  • A discussion on affiliated trends, key drivers and challenges, under an elaborate SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry. 
  • A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing contract manufacturing services to biopharmaceutical developers.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as growth of the overall biopharmaceutical market, cost of goods sold, and direct manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period 2020-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] commonly outsourced business operations (active pharmaceutical ingredients (APIs), finished dosage formulations (FDFs)), [B] types of expression systems used (mammalian, microbial and others), [C] scale of operation (preclinical, clinical and commercial), [D] company size (small, mid-sized and large / very large), [E] types of biologics manufactured (antibody, vaccine, cell therapy and other biologics) and [F] key geographical regions (North America (the US, Canada), Europe (the UK, France, Germany, Italy and Spain), Asia (China, India and Australia), Latin America, Middle East and North Africa). To account for the uncertainties associated with the manufacturing of biopharmaceuticals and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution. 

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders (arranged in alphabetical order):

  • Andrea Conforto (Sales & Marketing, Bioservices Director, Olon)
  • Astrid Brammer (Senior Manager Business Development, Richter-Helm)
  • Birgit Schwab (Senior Market Intelligence Manager, Rentschler Biotechnologie)
  • Christian Bailly (Director of CDMO, Pierre Fabre)
  • Claire Otjes (Marketing Manager, Batavia Biosciences)
  • David C Cunningham (Director Corporate Development, Goodwin Biotechnology) 
  • Dietmar Katinger(Chief Executive Officer, Polymun Scientific)
  • Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma) 
  • Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences)
  • Kevin Daley (Market Director Pharmaceuticals, Novasep) 
  • Mark Wright (ex-Site Head, Grangemouth, Piramal Healthcare)
  • Max Rossetto (General Manager – Business Development, Luina Bio)
  • Nicolas Grandchamp (R&D Leader, GEG Tech)
  • Raquel Fortunato (Chief Executive Officer, GenIbet Biopharmaceuticals) 
  • Sebastian Schuck (Director Global Business Development, WACKER BIOTECH Biotech) 
  • Stephen Taylor (Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies) 
  • Marco Schmeer (Project Manager, PlasmidFactory) and Tatjana Buchholz (ex-Marketing Manager, PlasmidFactory)
  • Tim Oldham (ex - Chief Executive Officer, Cell Therapies)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the biopharmaceutical contract manufacturing market in the mid to long term. 

Chapter 3 provides a general introduction to biopharmaceuticals and biopharmaceutical manufacturing processes. The chapter also includes an overview of the various expression systems used for the development of different types of biotherapeutic products. It features a brief overview of contract manufacturing, along with a detailed discussion on the need for outsourcing within the biopharmaceutical industry. We have also presented a list of commonly outsourced biomanufacturing activities. The chapter concludes with a discussion on the challenges faced by players currently engaged in the market.

Chapter 4 provides a detailed overview of the global biopharmaceutical contract manufacturing landscape. It includes information related to over 200 CMOs that are currently active in this domain. In addition, it features an in-depth analysis of the market, based on a number of parameters, such as such as year of establishment, company size, location of headquarters of the CMO, type of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), scale of operation (preclinical, clinical and commercial), types of expression systems used (mammalian, microbial and others), type of bioreactors used (single-use bioreactors and stainless steel bioreactors), mode of operation of bioreactors (batch, fed-batch and perfusion), bioprocessing capacity and type of packaging.

Chapter 5 provides a detailed landscape of biopharmaceutical manufacturing facilities in key regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa). It includes analysis and map representations based on location of these facilities, highlighting key provinces as the manufacturing hubs.

Chapter 6 features detailed profiles of some of the key players that are active in the biopharmaceutical contract manufacturing market in the North America. Each profile presents a brief overview of the company, its contract service offerings, financial information (if available), information related to manufacturing facilities, partnerships, recent developments (expansions) and an informed future outlook.

Chapter 7 features detailed profiles of some of the key players that are active in the biopharmaceutical contract manufacturing market in Europe. Each profile presents a brief overview of the company, its contract service offerings, financial information (if available), information related to manufacturing facilities, partnerships, recent developments (expansions) and an informed future outlook.

Chapter 8 features detailed profiles of some of the key players that are active in the biopharmaceutical contract manufacturing market in Asia and other regions of the world. Each profile presents a brief overview of the company, its contract service offerings, financial information (if available), information related to manufacturing facilities, partnerships, recent developments (expansions) and an informed future outlook.

Chapter 9 focuses on the key enablers in this domain, including certain niche product classes, such as ADCs, bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market. The chapter provides detailed a market overview, including information on the pipeline, and the presence of CMOs in each of the aforementioned segments. 

Chapter 10 is a case study focused on outsourcing of operations associated with biosimilars, which represents a major growth opportunity for biopharmaceutical CMOs. It provides an overview of biosimilars and captures information on the various CMOs that are actively involved in this segment of the biopharmaceutical market.

Chapter 11 is a case study comparing the key characteristics of small and large molecule drugs, along with information on the steps involved in their respective manufacturing processes. 

Chapter 12 is a case study focused on challenges associated with in-house manufacturing. It also provides details on the outsourcing trends in this domain, along with information related to various partnership models that are being used by various stakeholders to partner with CMOs. In addition, it features a list of recently approved biologics, with information on the type of biologic, target indication(s), developer and manufacturing approach adopted by the developer. Further, the chapter features a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource its operations.

Chapter 13 presents a qualitative analysis that highlights the various factors that need to be taken into consideration by biopharmaceutical therapeutics / drug developers while deciding whether to manufacture their respective products in-house or engage the services of CMOs.

Chapter 14 provides a detailed analysis of biopharmaceutical based manufacturing related initiatives of the big pharma players (shortlisted on the basis of the revenues generated by the top 10 pharmaceutical companies in 2019), featuring trends across various parameters, such as number of initiatives, year of initiative, purpose of initiative, type of initiative, scale of operation, types of biologics manufactured and type of product.

Chapter 15 features an elaborate analysis and discussion of the various collaborations and partnerships that have been inked amongst players since 2015. It includes a brief description on the various types of partnership models (which include product-based agreements, process-based agreements, licensing agreements, co-service agreements / ventures, R&D agreements and other outsourcing service agreements) that have been adopted by stakeholders in this domain. It also consists of a schematic representation showcasing the players that have established the maximum number of alliances related to the manufacturing of biologics. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents. 

Chapter 16 includes a detailed analysis of the mergers and acquisitions that have taken place in this space, highlighting the trend in the number of companies acquired from 2015-2020. The analysis also provides information on the key value drivers for these mergers and acquisitions and the corresponding acquisition deal multiples.

Chapter 17 presents an analysis of the recent expansions undertaken (since 2015) by various service providers for augmenting their respective biopharma contract manufacturing service portfolios, based on a number of parameters, including year of expansion, purpose of expansion (capacity expansion and new facility), types of biologics manufactured, geographical location of facility, and most active players (in terms of number of instances). 

Chapter 18 provides details on the funding instances and emerging technologies related to biomanufacturing processes.

Chapter 19 features a comprehensive analysis of the global / regional capacity of contract manufacturers that are engaged in the manufacturing of biopharmaceutical products. The analysis takes into consideration the individual development and manufacturing capacities of various stakeholders (small, mid-sized, large and very large CMOs / CDMOs) in the market, using data from both secondary and primary research. The study examines the distribution of global biopharmaceutical manufacturing capacity by scale of operation (preclinical / clinical, commercial), size of the company (small, mid-sized, large and very large), region of operation (North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia-Pacific (China, India, Japan, South Korea and Australia), Latin America, Middle East and North Africa).

Chapter 20 features a comprehensive analysis of the annual demand of biotherapeutics (in grams), taking into account the top 25 biologics, based on various relevant parameters, such as target patient population, dosing frequency and dose strength of the abovementioned products.

Chapter 21 presents a comprehensive market forecast analysis, highlighting the likely growth of the biologics manufacturing market till the year 2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] commonly outsourced business operations (active pharmaceutical ingredients (APIs), finished dosage formulations (FDFs), [B] expression system used (mammalian, microbial and others), [C] scale of operation (preclinical, clinical and commercial), [D] company size (small, mid-sized and large / very large), [E] types of biologics manufactured (antibody, vaccine, cell therapy and other biologics) and [F] key geographical regions (North America (US, Canada), Europe (UK, France, Germany, Italy and Spain), Asia (China India and Australia), Latin America, Middle East and North Africa.

Chapter 22 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of biopharmaceuticals manufacturing market, under a comprehensive SWOT framework.

Chapter 23 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the biopharmaceutical CMOs market, based on the research and analysis described in the previous chapters. It also provides a recap of some of the upcoming future trends, which, we believe, are likely to influence the growth of biopharmaceutical CMOs. 

Chapter 24 presents insights from the survey conducted for this study. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 25 contains the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the biopharmaceutical contract manufacturing domain. In this study, we spoke to (in alphabetical order) Andrea Conforto (Sales and Marketing, Bioservices Dierector, Olon), Astrid Brammer (Senior Manager Business Development, Richter-Helm), Birgit Schwab (Senior Market Intelligence Manager, Rentschler Biotechnologie), Christian Bailly (Director of CDMO, Pierre Fabre), Claire Otjes (Marketing Manager, Batavia Biosciences), David C Cunningham (Director Corporate Development, Goodwin Biotechnology), Dietmar Katinger (Chief Executive Officer, Polymun Scientific), Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma), Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences), Kevin Daley (Market Director Pharmaceuticals, Novasep), Mark Wright (ex-Site Head, Grangemouth, Piramal Healthcare), Max Rossetto (General Manager – Business Development, Luina Bio), Nicolas Grandchamp (R&D Leader, GEG Tech), Raquel Fortunato (Chief Executive Officer, GenIbet Biopharmaceuticals), Sebastian Schuck (Director Global Business Development, Wacker Biotech Biotech), Stephen Taylor (Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies), Marco Schmeer (Project Manager, PlasmidFactory) and Tatjana Buchholz (ex-Marketing Manager, PlasmidFactory) and Tim Oldham (ex-Chief Executive Officer, Cell Therapies).

Chapter 26 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 27 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3.    Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Biopharmaceuticals
3.3. Expression Systems for Biopharmaceuticals
3.3.1. Insect Expression Systems 
3.3.2. Mammalian Expression Systems
3.3.3. Microbial Expression Systems
3.3.3.1. Bacterial Expression Systems
3.3.3.2. Fungal Expression Systems
3.3.3.3. Yeast Expression Systems
3.3.4. Plant Expression Systems
3.3.5. Mammalian versus Microbial Expression Systems

3.4. Manufacturing Process of Biopharmaceuticals
3.4.1. Upstream Processing
3.4.2. Fermentation
3.4.3. Downstream Processing

3.5. Overview of Contract Manufacturing
3.6. Need for Outsourcing Biopharmaceutical Manufacturing Operations
3.6.1. Commonly Outsourced Manufacturing Operations for Biopharmaceuticals
3.6.2. Advantages of Outsourcing Biopharmaceutical Manufacturing Operations 
3.6.3. Risks and Challenges Associated with Outsourcing Biopharmaceutical Manufacturing Operations
3.7. Key Considerations while Selecting a Contract Manufacturing Partner
3.8. Future Perspectives

4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Biopharmaceutical Contract Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment 
4.2.2. Analysis by Company Size 
4.2.3. Analysis by Location of Headquarters 
4.2.4. Analysis by Type of Product
4.2.5. Analysis by Types of Biologics Manufactured 
4.2.6. Analysis by Scale of Operation
4.2.7. Analysis by Types of Expression Systems Used
4.2.8. Analysis by Type of Bioreactors 
4.2.9. Analysis by Mode of Operation of Bioreactors

5. MANUFACTURING FACILITIES OF BIOPHARMACEUTICAL CONTRACT MANUFACTURING ORGANIZATIONS (CMOs)
5.1. Chapter Overview
5.2. Key Assumptions and Methodology
5.3. Overall Landscape of Biopharmaceutical Contract Manufacturing Facilities
5.3.1. Analysis by Type of Product
5.3.2. Analysis by Scale of Operation
5.3.3. Analysis by Type of Expression System Used

5.4. Biopharmaceutical Contract Manufacturing Facilities in North America
5.5. Biopharmaceutical Contract Manufacturing Facilities in Europe
5.6. Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific

6. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN NORTH AMERICA
6.1. Chapter Overview
6.2. Biopharmaceutical Contract Manufacturing in the US: Regulatory Scenario
6.2.1. Impact of Current Political Situation

6.3. Leading Biopharmaceutical CMOs in North America
6.3.1. AGC Biologics
6.3.1.1. Company Overview
6.3.1.2. Service Portfolio
6.3.1.2.1. Process Development
6.3.1.2.2. cGMP Manufacturing
6.3.1.2.3. Quality and Regulatory
6.3.1.2.4. Process Validation
6.3.1.3. Financial Information
6.3.1.4. Manufacturing Facilities
6.3.1.5. Partnerships
6.3.1.6. Recent Developments
6.3.1.7. Future Outlook

6.3.2. Catalent (Catalent Pharma Solutions)
6.3.2.1. Company Overview
6.3.2.2. Service Portfolio
6.3.2.2.1. Cell Line Development
6.3.2.2.2. Manufacturing (Biomanufacturing)
6.3.2.2.3. ADCs and Bioconjugates Manufacturing
6.3.2.2.4. Biosimilars Development and Manufacturing
6.3.2.2.5. Proprietary Delivery and Fill / Finish Solutions
6.3.2.2.6. Analytical Services
6.3.2.3. Clinical Supply Services
6.3.2.4. Financial Information
6.3.2.5. Manufacturing Facilities
6.3.2.6. Partnerships
6.3.2.7. Recent Developments
6.3.2.8. Future Outlook

6.3.3. Cytiva (GE Healthcare) 
6.3.3.1. Company Overview
6.3.3.2. Service Portfolio
6.3.3.2.1. Biomanufacturing Services
6.3.3.2.2. Scientific Support
6.3.3.2.3. OptiRun Service Solutions
6.3.3.2.4. Instruments Qualification Services
6.3.3.3. Financial Information
6.3.3.4. Manufacturing Facilities
6.3.3.5. Partnerships
6.3.3.6. Recent Developments
6.3.3.7. Future Outlook

6.3.4. FUJIFILM Diosynth Biotechnologies
6.3.4.1. Company Overview
6.3.4.2. Service Portfolio
6.3.4.2.1. Strain Development
6.3.4.2.2. Process Development
6.3.4.2.3. GMP Contract Manufacturing
6.3.4.2.4. Analytical Solutions
6.3.4.3. Financial Information
6.3.4.4. Manufacturing Facilities
6.3.4.5. Partnerships
6.3.4.6. Recent Developments
6.3.4.7. Future Outlook

6.3.5. KBI Biopharma
6.3.5.1. Company Overview
6.3.5.2. Service Portfolio
6.3.5.2.1. Process Development
6.3.5.2.2. Analytical Development
6.3.5.2.3. GMP Manufacturing
6.3.5.2.4. Clinical Cell Therapy Support
6.3.5.3. Manufacturing Facilities
6.3.5.4. Partnerships
6.3.5.5. Future Outlook

6.3.6. Patheon (acquired by Thermo Fisher Scientific)  
6.3.6.1 Company Overview
6.3.6.2. Service Portfolio
6.3.6.2.1. Biologics
6.3.6.2.1.1. Drug Substance
6.3.6.2.2. Analytical Services
6.3.6.2.3. Product Development
6.3.6.2.4. Commercial Product Supply
6.3.6.3. Financial Information
6.3.6.4. Manufacturing Facilities
6.3.6.5. Partnerships
6.3.6.6. Recent Developments
6.3.6.7. Future Outlook

6.3.7. Piramal Pharma Solutions 
6.3.7.1 Company Overview
6.3.7.2. Service Portfolio
6.3.7.2.1. Antibody Drug Conjugation Services
6.3.7.2.2. Other Services
6.3.7.3. Financial Information
6.3.7.4. Manufacturing Facilities
6.3.7.5. Future Outlook

7. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN EUROPE
7.1. Chapter Overview
7.2. Biopharmaceutical Contract Manufacturing in Europe: Regulatory Scenario
7.2.1.  EMA’s cGMP Regulations

7.3. Leading Biopharmaceutical CMOs in Europe
7.3.1. Boehringer Ingelheim BioXcellence
7.3.1.1. Company Overview
7.3.1.2. Service Portfolio
7.3.1.2.1. Process Development
7.3.1.2.1.1. Expression Systems
7.3.1.2.1.2. Upstream Technology
7.3.1.2.1.3. Downstream Technology
7.3.1.2.1.4. Other Process Development Services
7.3.1.2.2. Quality Assurance
7.3.1.2.3. Fill / Finish
7.3.1.3. Financial Information
7.3.1.4. Manufacturing Facilities
7.3.1.5. Partnerships
7.3.1.6. Recent Developments
7.3.1.7. Future Outlook

7.3.2. Lonza
7.3.2.1. Company Overview
7.3.2.2. Service Portfolio
7.3.2.3. Manufacturing Services
7.3.2.4. Financial Information
7.3.2.5. Manufacturing Facilities
7.3.2.6. Partnerships
7.3.2.7. Recent Developments
7.3.2.8. Future Outlook

7.3.3. Novasep 
7.3.3.1 Company Overview
7.3.3.2. Service Portfolio
7.3.3.2.1. Services for Viruses and Viral Vectors
7.3.3.2.2. Services for Monoclonal Antibodies
7.3.3.2.3. Services for ADCs
7.3.3.2.4. Quality, Regulatory and Other Services
7.3.3.3. Financial Information
7.3.3.4. Manufacturing Facilities
7.3.3.5. Partnerships
7.3.3.6. Recent Developments
7.3.3.7. Future Outlook

7.3.4. Olon
7.3.4.1. Company Overview
7.3.4.2. Service Portfolio
7.3.4.3. Manufacturing Facilities
7.3.4.4. Future Outlook

7.3.5. Rentschler Biopharma 
7.3.5.1. Company Overview
7.3.5.2. Service Portfolio
7.3.5.2.1. Bioprocess Development
7.3.5.2.2. Biomanufacturing Services
7.3.5.2.3. Other Services
7.3.5.3. Manufacturing Facilities
7.3.5.4. Partnerships
7.3.5.5. Recent Developments
7.3.5.6. Future Outlook

7.3.6. Sandoz
7.3.6.1. Company Overview
7.3.6.2. Service Portfolio
7.3.6.3. Financial Information
7.3.6.4. Future Outlook

8. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN ASIA-PACIFIC AND THE REST OF THE WORLD
8.1. Chapter Overview
8.2. Biopharmaceutical Contract Manufacturing in China
8.2.1. Biopharmaceutical Contract Manufacturing in China: Regulatory Scenario
8.2.2. Challenges Faced while Outsourcing to China

8.3. Leading Biopharmaceutical CMOs in China
8.3.1. WuXi AppTec (WuXi Biologics)
8.3.1.1. Company Overview
8.3.1.2. Service Portfolio
8.3.1.2.1. Discovery Services
8.3.1.2.2. Development Services
8.3.1.2.3. Testing Services
8.3.1.2.4. Clinical Manufacturing Services
8.3.1.2.5. Fill / Finish Operations
8.3.1.3. Financial Information
8.3.1.4. Manufacturing Facilities
8.3.1.5. Partnerships
8.3.1.6. Recent Developments
8.3.1.7. Future Outlook

8.4. Biopharmaceutical Contract Manufacturing in India
8.4.1. Biopharmaceutical Contract Manufacturing in India: Regulatory Scenario
8.4.2. Challenges Faced while Outsourcing to India

8.5. Leading Biopharmaceutical CMOs in India
8.5.1. Kemwell Biopharma 
8.5.1.1. Company Overview
8.5.1.2. Service Portfolio
8.5.1.2.1. Development Services for Biopharmaceuticals
8.5.1.2.2. Manufacturing Services for Biopharmaceuticals
8.5.1.3. Manufacturing Facilities
8.5.1.4. Partnerships
8.5.1.5. Recent Developments
8.5.1.6. Future Outlook

8.6. Biopharmaceutical Contract Manufacturing in Japan
8.6.1. Biopharmaceutical Contract Manufacturing in Japan: Regulatory Scenario

8.7. Leading Biopharmaceutical CMOs in Japan
8.7.1. Minaris Regenerative Medicine
8.7.1.1. Company Overview
8.7.1.2. Service Portfolio
8.7.1.2.1. Manufacturing Development
8.7.1.2.2. GMP Manufacturing
8.7.1.3. Manufacturing Facilities
8.7.1.4. Recent Developments
8.7.1.5. Future Outlook
8.7.2. Takara Bio
8.7.2.1. Company Overview
8.7.2.2. Service Portfolio
8.7.2.3. Financial Information
8.7.2.4. Manufacturing Facilities
8.7.2.5. Future Outlook

8.8. Biopharmaceutical Contract Manufacturing in South Korea
8.8.1. Biopharmaceutical Contract Manufacturing in South Korea: Regulatory Scenario

8.9. Leading Biopharmaceutical CMOs in South Korea
8.9.1. Celltrion
8.9.1.1. Company Overview
8.9.1.2. Service Portfolio
8.9.1.3. Financial Information
8.9.1.4. Manufacturing Facilities
8.9.1.5. Future Outlook

8.9.2. Samsung BioLogics
8.9.2.1. Company Overview
8.9.2.2. Service Portfolio
8.9.2.2.1. Process Development
8.9.2.2.2. Analytical Services
8.9.2.2.3. cGMP Manufacturing Services
8.9.2.2.4. Aseptic Fill / Finish
8.9.2.2.5. Quality Services
8.9.2.2.6. Other Services
8.9.2.3. Financial Information
8.9.2.4. Manufacturing Facilities
8.9.2.5. Partnerships
8.9.2.6. Recent Developments
8.9.2.7. Future Outlook

8.10. Biopharmaceutical Contract Manufacturing in Australia
8.10.1. Biopharmaceutical Contract Manufacturing in Australia: Regulatory Scenario

8.11. Leading Biopharmaceutical CMOs in Australia
8.11.1. Cell Therapies
8.11.1.1. Company Overview
8.11.1.2. Service Portfolio
8.11.1.3. Manufacturing Facilities
8.11.1.4. Partnerships
8.11.1.5. Future Outlook

8.11.2. Luina Bio
8.11.2.1. Company Overview
8.11.2.2. Service Portfolio
8.11.2.2.1. Microbial Products
8.11.2.2.2. Vaccines
8.11.2.2.3. Support Services
8.11.2.2.4. Quality-related Services
8.11.2.3. Manufacturing Facilities
8.11.2.4. Partnerships
8.11.2.5. Recent Developments
8.11.2.6. Future Outlook

9. NICHE BIOPHARMACEUTICAL SECTORS
9.1. Chapter Overview
9.2. Bispecific Antibodies
9.2.1. Introduction
9.2.2. Pipeline Analysis
9.2.2.1.    Bispecific Antibody Therapeutics: Clinical Pipeline
9.2.2.2. Bispecific Antibody Therapeutics: Early Stage Pipeline
9.2.2.3. Multivalent Drug Candidates
9.2.3. Analysis by Phase of Development
9.2.4. Analysis by Target Indication
9.2.5. Bispecific Antibody Therapeutics: List of Technology Providers
9.2.6. Key Manufacturing Considerations and Challenges
9.2.7. Contract Manufacturing Scenario
9.2.7.1. CMOs Offering Services for Bispecific Antibodies

9.3. Antibody Drug Conjugates (ADCs)
9.3.1. Components of ADCs
9.3.1.1. Antibody
9.3.1.2. Cytotoxin
9.3.1.3. Linker
9.3.2. Manufacturing Process
9.3.3. Pipeline Analysis
9.3.3.1. ADC Therapeutics: Clinical Pipeline
9.3.4. Analysis by Phase of Development
9.3.5. Analysis by Target Indication
9.3.6. Key Technology Players: Analysis by Number of ADC Therapeutics
9.3.7. Novel Drug Conjugates
9.3.8. Key Manufacturing Considerations and Challenges 
9.3.9. Contract Manufacturing Scenario
9.3.9.1. CMOs Offering Services for ADCs

9.4. Cell Therapies
9.4.1.     Introduction
9.4.2. Current Market Landscape
9.4.3. Cell Therapy Manufacturing
9.4.3.1. Cell Therapy Manufacturing Models
9.4.3.1.1. Centralized Manufacturing
9.4.3.1.2. Decentralized Manufacturing
9.4.4. Key Manufacturing Considerations and Challenges
9.4.5. Factors Influencing Cell Therapy Manufacturing
9.4.5.1. Characterization
9.4.5.2. Cost of Goods
9.4.5.3. Automation of Cell Therapy Manufacturing
9.4.6. Analysis by Types of Cells Manufactured
9.4.7. Stem Cell Therapies: Analysis by Phase of Development
9.4.8. T-Cell Therapies: Analysis by Phase of Development
9.4.9. Contract Manufacturing Scenario
9.4.9.1. CMOs Offering Services for Cell Therapy

9.5. Gene Therapy
9.5.1. Gene Therapy Market: Pipeline Analysis
9.5.1.1. Analysis by Stage of Development
9.5.1.2. Analysis by Phase of Development
9.5.1.3. Analysis by Type of Vector Used
9.5.1.3.1. Clinical Pipeline
9.5.1.3.2. Preclinical Pipeline
9.5.1.4. Analysis by Target Indication
9.5.1.4.1. Clinical and Commercial Pipeline
9.5.1.4.1. Preclinical Pipeline
9.5.1.5. Analysis by Location of Manufacturing Facility
9.5.1.6 Analysis by Type of Viral Vector Used
9.5.2. Contract Manufacturing Scenario
9.5.2.1. CMOs Offering Services for Viral Vectors

9.6. Plasmid DNA 
9.6.1. Introduction
9.6.2. Analysis by Location of Manufacturing Facility
9.6.3. Contract Manufacturing Scenario
9.6.3.1. CMOs Offering Services for Plasmid DNA

10. CASE STUDY: OUTSOURCING OF BIOSIMILARS
10.1. Chapter Overview
10.2. Biosimilars: An Introduction
10.3. Biosimilars: Development Stages
10.4. Regulatory Requirements for Licensing of Biosimilars
10.5. Need for Outsourcing Biosimilar Development and Manufacturing 
10.6. Impact of Biosimilars on the Global Contract Manufacturing Market
10.6.1. Pipeline Analysis of Biosimilars, 2013 versus 2020
10.7. Biosimilars Contract Manufacturing Service Providers
10.8. Challenges Associated with Outsourcing of Biosimilar Manufacturing Operations 

11. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULES DRUGS / THERAPIES
11.1. Chapter Overview
11.2. Small Molecule and Large Molecule Drugs / Therapies
11.2.1. Comparison of General Characteristics
11.2.2. Comparison of Key Specifications
11.2.3. Comparison of Manufacturing Process
11.2.4. Comparison of Key Manufacturing Challenges

12. CASE STUDY: IN-HOUSE MANUFACTURING
12.1. Chapter Overview
12.2. In-House Manufacturing
12.2.1. Benefits Associated with In-House Manufacturing
12.2.2. Risks Associated with In-House Manufacturing
12.3. Outsourcing in the Biopharmaceutical Industry
12.3.1. Types of Outsourcing Partners

12.4. Manufacturing Approaches Used for Approved Biologics (2016-2020)
12.4.1. Approved Biologics: Analysis by Company Size and Type of Manufacturing Model Adopted
12.4.2. Approved Biologics: Analysis by Company Size and Types of Biologics 
12.5. Choosing the Right Strategy: In-House Manufacturing versus Outsourcing

13. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
13.1. Chapter Overview
13.2. Assumptions and Key Parameters 
13.3. Biopharmaceutical Contract Manufacturers: Make versus Buy Decision Making
13.3.1. Scenario 1
13.3.2. Scenario 2
13.3.3. Scenario 3
13.3.4. Scenario 4
13.4. Conclusion

14. BIG PHARMA INITIATIVES 
14.1. Chapter Overview
14.2. List of Biopharmaceutical Manufacturing Initiatives of Big Pharma Players
14.2.1. Analysis by Number of Initiatives
14.2.2. Analysis by Year of Initiative
14.2.3. Analysis by Purpose of Initiative
14.2.4. Analysis by Type of Initiative
14.2.4.1. Analysis by Type of Partnership
14.2.4.2. Analysis by Type of Expansion
14.2.5. Analysis by Scale of Operation
14.2.6. Analysis by Types of Biologics Manufactured
14.2.7. Analysis by Year of Initiative and Company
14.2.8. Analysis by Purpose of Initiative and Company
14.2.9. Analysis by Year and Type of Initiative
14.2.10. Analysis by Type of Region of Expansion and Company
14.2.11 Analysis by Types of Biologics Manufactured and Company
14.3. Competitive Benchmarking of Big Pharma Players
14.3.1. Harvey Ball Analysis: Big Pharma Investment Summary

15. PARTNERSHIPS AND COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models
15.3. Biopharmaceutical Contract Manufacturing: List of Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.3. Analysis by Focus Area
15.3.4. Analysis by Focus Area and Type of Partnership Model Adopted
15.3.5. Analysis by Year and Type of Partnership Model Adopted
15.3.6. Analysis by Types of Biologics Manufactured
15.3.7. Analysis by Year and Types of Biologics Manufactured
15.3.8. Analysis by Types of Biologics Manufactured and Type of Partnership Model Adopted
15.3.9. Analysis by Types of Biologics Manufactured and Geography
15.3.10. Analysis by Therapeutic Area
15.3.11. Most Active Players: Analysis by Number of Partnerships
15.3.12. Regional Analysis
15.3.13. Local and Intracontinental Agreements

16. MERGERS AND ACQUISITIONS
16.1.     Chapter Overview
16.2. Merger and Acquisition Models
16.3. Acquisition Models
16.4. Biopharmaceutical Contract Manufacturing: Mergers and Acquisitions 
16.4.1. Cumulative Year-wise Trend
16.4.2. Analysis by Type of Acquisition
16.4.3. Analysis by Geographical Activity
16.4.3.1. Mergers and Acquisitions: Continent-wise Distribution
16.4.3.2. Mergers and Acquisitions: Country-wise Distribution
16.4.4. Mergers and Acquisitions: Intercontinental and Intracontinental Deals
16.4.5. Most Active Acquirers: Analysis by Number of Acquisitions
16.4.6 Analysis by Key Value Drivers
16.2.6.1. Analysis by Key Value Drivers and Year of Acquisition
16.2.6.2. Analysis by Key Value Drivers and Types of Biologics Manufactured
16.2.6.3. Analysis by Types of Biologics Manufactured
16.3. Key Acquisitions: Deal Multiples

17. RECENT EXPANSIONS
17.1. Chapter Overview
17.2. Biopharmaceutical Contract Manufacturing Market: Expansions
17.2.1. Cumulative Year-wise Distribution
17.2.2. Analysis by Purpose of Facility Expansion
17.2.3. Analysis by Year and Purpose of Expansion
17.2.4. Analysis by Types of Biologics Manufactured
17.2.5. Analysis by Types of Biologics Manufactured and Purpose of Expansion
17.2.6. Analysis by Location of Manufacturing Facility
17.2.7. Regional Analysis
17.2.8. Most Active Players: Analysis by Number of Recent Expansions
17.2.9. Analysis by Location of Headquarters and Purpose of Expansion
17.2.10. Facility Expansions: 2016-2018 and 2016-2020 Scenario

18. RECENT DEVELOPMENTS
18.1. Biopharmaceutical Contract Manufacturing Market: Funding Instances
18.2. Technological Advancements
18.2.1. Single Use Technology
18.2.2. Process Analytical Technology (PAT)
18.2.3. Continuous Processing
18.2.4. Quality by Design (QbD) in Bio-Processing
18.2.5. Modular / Podular Biopharma Facilities

19. CAPACITY ANALYSIS
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Biopharmaceutical CMOs: Global Production Capacity
19.3.1. Analysis by Company Size 
19.3.2. Analysis by Type of Expression Systems Used
19.3.3. Analysis by Scale of Operation
19.3.4. Analysis by Region
19.3.4.1. Capacity Analysis: North America
19.3.4.2. Capacity Analysis: Europe
19.3.4.3. Capacity Analysis: Asia-Pacific
19.4. Conclusion

20. DEMAND ANALYSIS
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Overall Annual Demand for Biopharmaceuticals Market, 2020-2030
20.3.1. Analysis by Therapeutic Area
20.4. Relationship Between Annual Demand and Capacity
20.5. Demand for Emerging Novel Biologics
20.5.1. ADC Therapeutics: Overall Annual Demand
20.5.2. ADC Therapeutics: Demand and Supply Analysis
20.6. Global Demand for Cell Therapy Manufacturing

21. MARKET SIZING AND OPPORTUNITY SIZING
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Global Biopharmaceutical Contract Manufacturing Market, 2020-2030
21.3.1. Biopharmaceutical Contract Manufacturing Market for API Manufacturing, 2020-2030
21.3.2. Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, 2020-2030
21.3.3. Biopharmaceutical Contract Manufacturing Market for Others Manufacturing, 2020-2030
21.4. Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Type of Expression Systems Used
21.5. Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation
21.6. Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Company Size
21.7. Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Types of Biologics Manufactured
21.8. Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Geography

21.8.1. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030
21.8.1.1. Biopharmaceutical Contract Manufacturing Market in the US, 2020-2030
21.8.1.2. Biopharmaceutical Contract Manufacturing Market in Canada, 2020-2030
21.8.1.3. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Mammalian Cell-based Operations
21.8.1.4. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Microbial Cell-based Operations
21.8.1.5. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Other Expression System-based Operations
21.8.1.6. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Operations
21.8.1.7. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Commercial Operations
21.8.1.8. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Small Companies
21.8.1.9. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Mid-sized Companies
21.8.1.10. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies
21.8.1.11. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Antibody Therapeutics
21.8.1.12. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Vaccines
21.8.1.13. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Cell Therapies

21.8.2. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030
21.8.2.1. Biopharmaceutical Contract Manufacturing Market in Italy, 2020-2030
21.8.2.2. Biopharmaceutical Contract Manufacturing Market in Germany, 2020-2030
21.8.2.3. Biopharmaceutical Contract Manufacturing Market in France, 2020-2030
21.8.2.4. Biopharmaceutical Contract Manufacturing Market in Spain, 2020-2030
21.8.2.5. Biopharmaceutical Contract Manufacturing Market in the UK, 2020-2030
21.8.2.6. Biopharmaceutical Contract Manufacturing Market in Rest of Europe, 2020-2030
21.8.2.7. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Mammalian Cell-based Operations
21.8.2.8. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Microbial Cell-based Operations
21.8.2.9. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Other Expression System-based Operations
21.8.2.10. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Operations
21.8.2.11. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Commercial Operations
21.8.2.12. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Small Companies
21.8.2.13. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies
21.8.2.14. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies
21.8.2.15. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Antibody Therapeutics
21.8.2.16. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Vaccines
21.8.2.17. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Cell Therapies

21.8.3. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030
21.8.3.1. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030
21.8.3.2. Biopharmaceutical Contract Manufacturing Market in India, 2020-2030
21.8.3.3. Biopharmaceutical Contract Manufacturing Market in South Korea, 2020-2030
21.8.3.4. Biopharmaceutical Contract Manufacturing Market in Japan, 2020-2030
21.8.3.5. Biopharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, 2020-2030
21.8.3.6. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Mammalian Cell-based Operations
21.8.3.7. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Microbial Cell-based Operations
21.8.3.8. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Other Expression System-based Operations
21.8.3.9. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Preclinical / Clinical Operations
21.8.3.10. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Commercial Scale Operations
21.8.3.11. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Small Companies
21.8.3.12. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Mid-sized Companies
21.8.3.13. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Large / Very Large Companies
21.8.3.14. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Antibody Therapeutics
21.8.3.15. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Vaccines
21.8.3.16. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Cell Therapies
21.8.4. Biopharmaceutical Contract Manufacturing Market in Latin America, 2020-2030
21.8.5. Biopharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2020-2030

22. SWOT ANALYSIS
22.1 Chapter Overview
22.2. Strengths
22.3. Weaknesses
22.4. Opportunities
22.5. Threats
22.6. Comparison of SWOT Factors
22.7. Conclusion

23. FUTURE OF THE BIOPHARMACEUTICAL CMO MARKET
23.1. Chapter Overview
23.2. Outsourcing Activities to Witness Significant Growth in the Coming Years
23.3. Shift from One-time Contracts to Strategic Partnerships
23.4. Integration / Adoption of New and Innovative Technologies
23.4.1. Single use Bioreactors
23.4.2. Novel Bioprocess Techniques
23.4.3. Bioprocess Automation
23.5. Focus on Niche Therapeutic Areas
23.6. Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment
23.7. Capability and Expertise Expansions by CMOs to become One-Stop-Shops
23.8. Offshoring Outsourcing Activities to Maximize Profits and Expand Existing Capacities
23.9. Increase in Financial Inflow and Outsourcing Budgets
23.10. Challenges Faced by both Sponsors and Service Providers
23.10.1. Concerns Related to Single Use Systems
23.10.2. Issues Related to Capacity Fluctuations

23.11. Concluding Remarks

24. SURVEY ANALYSIS
24.1. Chapter Overview
24.1.1. Overview of Respondents
24.1.2. Analysis by Designation of Respondents
24.2. Analysis by Biologics Manufacturing Expertise
24.3. Analysis by Scale of Manufacturing
24.4. Analysis by Location of Production Facilities
24.5. Analysis by Type of Expression Systems Used
24.6. Analysis by Type of Bioreactors
24.7. Analysis by Mode of Operation of Bioreactors

25. INTERVIEW TRANSCRIPTS
25.1. Chapter Overview
25.2. Andrea Conforto, Sales & Marketing – Bioservices Director, Olon
25.3. Astrid Brammer, Senior Manager Business Development, Richter-Helm
25.4. Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie (Q2 2015)
25.5. Christian Bailly, Director of CDMO, Pierre Fabre
25.6. Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
25.7. David C Cunningham, Director Corporate Development, Goodwin Biotechnology
25.8. Dietmar Katinger, Chief Executive Officer, Polymun Scientific
25.9. Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma
25.10. Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences
25.11. Kevin Daley, Director Pharmaceuticals, Novasep
25.12. Mark Wright, ex-Site Head, Grangemouth, Piramal Healthcare
25.13. Max Rossetto, General Manager – Business Development, Luina Bio
25.14. Nicolas Grandchamp, R&D Leader, GEG Tech
25.15. Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals
25.16. Sebastian Schuck, Head of Business Development, Wacker Biotech
25.17. Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies
25.18. Marco Schmeer, Ex-Project Manager And Tatjana Buchholz, Marketing Manager, Plasmid Factory
25.19. Tim Oldham (ex-Chief Executive Officer, Cell Therapies

26. APPENDIX 1: TABULATED DATA
 
27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Types of Biopharmaceuticals
Figure 3.2 Types of Expression Systems Used for the Production of Biopharmaceuticals
Figure 3.3 Stages of the Biomanufacturing Process
Figure 3.4 Types of Third-Party Service Providers
Figure 3.5 Commonly Outsourced Biopharmaceutical Contract Manufacturing Operations
Figure 4.1 Biopharmaceutical CMOs: Distribution by Year of Establishment
Figure 4.2 Biopharmaceutical CMOs: Distribution by Company Size
Figure 4.3 Biopharmaceutical CMO: Distribution by Location of Headquarters (Region-
Figure 4.4 Biopharmaceutical CMO: Distribution by Location of Headquarters (Country-wise)
Figure 4.5 Biopharmaceutical CMOs: Distribution by Company Size, Year of Establishment and Location of Headquarters
Figure 4.6 Biopharmaceutical CMOs: Distribution by Type of Product
Figure 4.7 Biopharmaceutical CMOs: Distribution by Types of Biologics Manufactured
Figure 4.8 Biopharmaceutical CMOs: Distribution by Types of Biologics Manufactured and
Figure 4.9 Biopharmaceutical CMOs: Distribution by Types of Biologics Manufactured and Company Size
Figure 4.10 Biopharmaceutical CMOs: Distribution by Scale of Operation
Figure 4.11 Biopharmaceutical CMOs: Distribution by Types of Biologics Manufactured and Scale of Operation
Figure 4.12 Biopharmaceutical CMOs: Distribution by Types of Expression Systems Used
Figure 4.13 Biopharmaceutical CMOs: Distribution by Types of Expression Systems Used and Location of Headquarters
Figure 4.14 Biopharmaceutical CMOs: Distribution by Types of Bioreactors
Figure 4.15 Biopharmaceutical CMOs: Distribution by Mode of Operation of Bioreactors
Figure 5.1 Distribution of Biopharmaceutical Contract Manufacturers by Location of Manufacturing Facilities
Figure 5.2 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Type of Product
Figure 5.3 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Scale of Operation
Figure 5.4 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Types of Expression Systems Used
Figure 5.5 Biopharmaceutical Contract Manufacturing Facilities: North America
Figure 5.6 Biopharmaceutical Contract Manufacturing Facilities: Europe
Figure 5.7 Biopharmaceutical Contract Manufacturing Facilities: Asia-Pacific
Figure 6.1 Biopharmaceutical Industry: The US Market Scenario
Figure 6.2 Biopharmaceutical Contract Manufacturing in the US: Growth Drivers and Challenges
Figure 6.3 US FDA Guidelines: Elements of a Quality Agreement
Figure 6.4 US FDA Guidelines: Key Considerations for Biologic Manufacturing Operations
Figure 6.5 AGC: Annual Revenues (JPY Billion)
Figure 6.6 Catalent: Service Portfolio
Figure 6.7 Catalent: Biosimilars Service Portfolio
Figure 6.8 Catalent: Annual Revenues (USD Million)
Figure 6.9 Cytiva: Service Portfolio
Figure 6.10 Cytiva: Annual Revenues (USD Million)
Figure 6.11 FUJIFILM Diosynth Biotechnologies: Service Portfolio
Figure 6.12 FUJIFILM Diosynth Biotechnologies: Annual Revenues (JPY Billion)
Figure 6.13 FUJIFILM Holdings: Annual Revenues by Business Divisions (JPY Billion)
Figure 6.14 KBI Biopharma: Service Portfolio
Figure 6.15 Patheon: Service Portfolio
Figure 6.16 Patheon: Services and Solutions for Biologics
Figure 6.17 Patheon: Annual Revenues (USD Million)
Figure 6.18 Piramal Enterprises: Annual Revenues (INR Billion)
Figure 7.1 Biopharmaceutical Contract Manufacturing in Europe: Growth Drivers and Challenges
Figure 7.2 EMA GMP Guidelines: Key Considerations of the Contract Giver, Contract Acceptor and the Contract
Figure 7.3 Boehringer Ingelheim BioXcellence: Service Portfolio
Figure 7.4 Boehringer Ingelheim: Annual Revenues (EUR Billion)
Figure 7.5 Lonza: Service Portfolio
Figure 7.6 Lonza: Annual Revenues (CHF Billion)
Figure 7.7 Lonza: Revenues by Business Divisions (CHF Billion)
Figure 7.8 Novasep: Products Portfolio
Figure 7.9 Novasep: Annual Revenues (EUR Million)
Figure 7.10 Rentschler Biopharma: Service Portfolio
Figure 7.11 Sandoz: Annual Revenues (USD Billion)
Figure 8.1 Chinese Regulatory Guidelines: Key Considerations of the Contract Giver
Figure 8.2 Chinese Regulatory Guidelines: Key Considerations of the Contract Acceptor
Figure 8.3 Chinese Regulatory Guidelines: Key Aspects of the Contract
Figure 8.4 Biopharmaceutical Contract Manufacturing in China: Challenges
Figure 8.5 WuXi Biologics: Service Portfolio
Figure 8.6 Wuxi Biologics: Annual Revenues (RMB Million)
Figure 8.7 Biopharmaceutical Contract Manufacturing in India: Growth Drivers
Figure 8.8 Biopharmaceutical Contract Manufacturing in India: Challenges
Figure 8.8 Minaris Regenerative Medicine: Service Portfolio
Figure 8.9 Takara Bio: Service Portfolio
Figure 8.10 Takara Bio: Annual Revenues (CNY Billion)
Figure 8.11 Celltrion: Service Portfolio
Figure 8.12 Celltrion: Annual Revenues (KRW Billion)
Figure 8.13 Samsung BioLogics: Service Portfolio
Figure 8.14 Samsung BioLogics: Annual Revenues from CMO Operations (KRW Billion)
Figure 8.15 Cell Therapies: Service Portfolio
Figure 8.16 Luina Bio: Service Portfolio
Figure 9.1 Structure of a Bispecific Antibody
Figure 9.2 Bispecific Antibody Therapeutics Pipeline: Distribution by Phase of Development
Figure 9.3 Bispecific Antibody Therapeutics Pipeline: Distribution by Target Indication
Figure 9.4 Structure of an Antibody Drug Conjugate (ADC)
Figure 9.5 ADCs Clinical Pipeline: Distribution by Phase of Development
Figure 9.6 ADCs Clinical and Commercial Pipeline: Distribution by Target Indication
Figure 9.7 ADCs Clinical and Commercial Pipeline: Distribution by Key Technology Providers
Figure 9.8 Decentralized Manufacturing: Process Model
Figure 9.9 Cell Therapy Manufacturing: Challenges and Growth Drivers
Figure 9.10 Cell Therapy: Potency as Critical Quality Attribute
Figure 9.11 Stem Cell Therapies: Distribution by Phase of Development
Figure 9.12 T-Cell Therapies: Distribution by Phase of Development
Figure 9.13 Gene Therapies: Distribution by Stage of Development
Figure 9.14 Gene Therapies: Distribution by Phase of Development
Figure 9.15 Gene Therapies Clinical and Commercial Pipeline: Distribution by Type of Vector Used
Figure 9.16 Gene Therapies Preclinical Pipeline: Distribution by Type of Vector Used
Figure 9.17 Gene Therapies Clinical and Commercial Pipeline: Distribution by Target Indication
Figure 9.18 Gene Therapies Preclinical Pipeline: Distribution by Target Indication
Figure 9.19 Viral Vector Manufacturers: Distribution by Location of Manufacturing Facility
Figure 9.20 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
Figure 10.1 Manufacturing Stages of a Biosimilar Product
Figure 10.2 Analytical and Functional Characterization Methods for Key Biosimilar Product
Figure 10.3 Regulatory Process Adopted for Licensing of a Biosimilar Product
Figure 10.4 Need for Outsourcing Biosimilar Manufacturing Operations
Figure 10.5 Pipeline Analysis of Biosimilars, 2013 versus 2020
Figure 10.6 Challenges Associated with Outsourcing Biosimilar Manufacturing Operations
Figure 11.1 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval, 2005-2020
Figure 11.2 Small Molecules versus Large Molecules: Comparison of Manufacturing Process
Figure 12.1 Benefits Associated with In-House Manufacturing
Figure 12.2 Risks Associated with In-House Manufacturing
Figure 12.3 Advantages and Disadvantages of Different Types of Outsourcing Partnerships
Figure 12.4 Approved Biologics: Distribution by Company Size and Type of Manufacturing Model Adopted
Figure 12.5 Approved Biologics: Distribution by Company Size and Types of Biologics Manufactured
Figure 13.1 Make versus Buy Decision Making Framework
Figure 13.2 Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 14.1 Big Pharma Players: Distribution by Number of Biopharmaceutical Contract Manufacturing Focused Initiatives, 1980-2020
Figure 14.2 Big Pharma Players: Cumulative Distribution by Year of Initiative
Figure 14.3 Big Pharma Players: Distribution by Purpose of Initiative
Figure 14.4 Big Pharma Players: Distribution by Type of Initiative
Figure 14.5 Big Pharma Players: Distribution by Type of Partnership
Figure 14.6 Big Pharma Players: Distribution by Type of Expansion
Figure 14.7 Big Pharma Players: Distribution by Scale of Operation
Figure 14.8 Big Pharma Players: Distribution by Types of Biologics Manufactured
Figure 14.9 Big Pharma Players: Distribution by Year of Initiative and Company
Figure 14.10 Big Pharma Players: Distribution by Purpose of Initiative and Company
Figure 14.11 Big Pharma Players: Distribution by Year and Type of Initiative
Figure 14.12 Big Pharma Players: Distribution by Region of Expansion and Company
Figure 14.13 Big Pharma Players: Distribution by Types of Biologics Manufactured and Company
Figure 14.14 Harvey Ball Analysis: Big Pharma Investment Summary
Figure 15.1 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2020
Figure 15.2 Partnerships and Collaborations: Distribution by Type of Partnership Model Adopted
Figure 15.3 Partnerships and Collaborations: Distribution by Focus Area
Figure 15.4 Partnerships and Collaborations: Distribution by Focus Area and Type of Partnership Model Adopted
Figure 15.5 Partnerships and Collaborations: Distribution by Year and Type of Partnership Model Adopted
Figure 15.6 Partnerships and Collaborations: Distribution by Types of Biologics Manufactured
Figure 15.7 Partnerships and Collaborations: Distribution by Year and Types of Biologics Manufactured
Figure 15.8 Partnerships and Collaborations: Distribution by Types of Biologics Manufactured and Type of Partnership Model
Figure 15.9 Partnerships and Collaborations: Distribution by Types of Biologics Manufactured and Geography
Figure 15.10 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 15.11 Most Active Players: Distribution by Number of Partnerships
Figure 15.12 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 15.13 Partnerships and Collaborations: Distribution by Geographical Location (Local and International)
Figure 16.1 Mergers and Acquisitions: Year-Wise Cumulative Trend (2015- 2020)
Figure 16.2 Mergers and Acquisitions: Distribution by Type of Acquisition
Figure 16.3 Mergers and Acquisitions: Distribution by Region (Continent-wise)
Figure 16.4 Mergers and Acquisitions: Distribution by Region (Country-wise)
Figure 16.5 Mergers and Acquisitions: Distribution by Intercontinental and Intracontinental Deals
Figure 16.6 Most Active Acquirers: Distribution by Number of Acquisitions
Figure 16.7 Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 16.8 Mergers and Acquisitions: Distribution by Key Value Drivers and Year of Acquisition
Figure 16.9 Mergers and Acquisitions: Distribution by Types of Biologics Manufactured
Figure 16.10 Heat Map Analysis: Distribution by Types of Biologics Manufactured and Key Value Drivers
Figure 16.11 Mergers and Acquisitions: Deal Multiples Based on Revenue
Figure 17.1 Facility Expansions: Cumulative Year-wise Trend, 2016-2020
Figure 17.2 Facility Expansions: Distribution by Purpose of Expansion
Figure 17.3 Facility Expansions: Distribution by Year and Purpose of Expansion
Figure 17.4 Facility Expansions: Distribution by Types of Biologics Manufactured
Figure 17.5 Facility Expansions: Distribution by Types of Biologics Manufactured and Purpose of Expansion
Figure 17.6 Facility Expansions: Distribution by Location of Manufacturing Facility (Region-wise)
Figure 17.7 Facility Expansions: Distribution by Location of Manufacturing Facility (Country-wise)
Figure 17.8 Facility Expansions: Most Active Players
Figure 17.9 Facility Expansions: Distribution by Location of Headquarters and Purpose of Expansion
Figure 17.10 Facility Expansions: Regional Comparison 2016-2018 and 2016-2020 Scenario
Figure 19.1 Biopharma CMOs Global Capacity: Distribution by Range of Installed Capacity
Figure 19.2 Capacity Analysis: Distribution by Company Size
Figure 19.3 Capacity Analysis: Global Contract Biomanufacturing Capacity based on Types of Expression Systems Used
Figure 19.4 Capacity Analysis: Global Contract Biomanufacturing Capacity based on Scale of Operation
Figure 19.5 Capacity Analysis: Regional Distribution of Biopharmaceutical CMOs
Figure 19.6 Capacity Analysis: Contract Biomanufacturing Capacity in the US
Figure 19.7 Capacity Analysis: Contract Biomanufacturing Capacity in Canada
Figure 19.8 Capacity Analysis: Contract Biomanufacturing Capacity in the UK
Figure 19.9 Capacity Analysis: Contract Biomanufacturing Capacity in Germany
Figure 19.10 Capacity Analysis: Contract Biomanufacturing Capacity in France
Figure 19.11 Capacity Analysis: Contract Biomanufacturing Capacity in Italy
Figure 19.12 Capacity Analysis: Contract Biomanufacturing Capacity in Spain
Figure 19.13 Capacity Analysis: Contract Biomanufacturing Capacity in Rest of Europe
Figure 19.14 Capacity Analysis: Contract Biomanufacturing Capacity in China
Figure 19.15 Capacity Analysis: Regional Contract Biomanufacturing Capacity in South Korea
Figure 19.16 Capacity Analysis: Regional Contract Biomanufacturing Capacity in Taiwan
Figure 19.17 Capacity Analysis: Regional Contract Biomanufacturing Capacity in India
Figure 19.18 Capacity Analysis: Regional Contract Biomanufacturing Capacity in Japan
Figure 19.19 Capacity Analysis: Regional Contract Biomanufacturing Capacity in Rest of Asia-Pacific
Figure 20.1 Demand Analysis: Annual Demand for Biopharmaceutical Manufacturing, 2020-2030 (in kg)
Figure 20.2 Demand Analysis: Distribution of Annual Demand by Therapeutic Area
Figure 20.3 Biologics: Demand and Supply Scenario, 2020-2030 (Million Liters)
Figure 20.4 Demand Analysis: Annual Demand for ADC Therapeutics (in kg), 2020-2030
Figure 20.5 ADC Therapeutics: Demand and Supply Scenario, 2020-2030
Figure 20.6 Global Demand for Cell Therapies, 2019-2030 (Number of Patients)
Figure 20.7 Global Demand for Cell Therapies, 2019-2030 (Billion Cells)
Figure 21.1 Biopharmaceutical Contract Manufacturing: Market Forecast Framework
Figure 21.2 Global Biopharmaceutical Contract Manufacturing Market, 2020-2030 (USD Billion)
Figure 21.3 Biopharmaceutical Contract Manufacturing Market for API Manufacturing, 2020-2030 (USD Billion)
Figure 21.4 Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, 2020-2030 (USD Billion)
Figure 21.5 Biopharmaceutical Contract Manufacturing Market for Others, 2020-2030 (USD Billion)
Figure 21.6 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Types of Expression Systems Used (USD Billion)
Figure 21.7 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation (USD Billion)
Figure 21.8 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Company Size (USD Billion)
Figure 21.9 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Types of Biologics Manufactured (USD Billion)
Figure 21.10 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Geography (USD Billion)
Figure 21.11 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030 (USD Billion)
Figure 21.12 Biopharmaceutical Contract Manufacturing Market in the US, 2020-2030 (USD Billion)
Figure 21.13 Biopharmaceutical Contract Manufacturing Market in Canada, 2020-2030 (USD Billion)
Figure 21.14 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
Figure 21.15 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
Figure 21.16 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Other Expression System-based Operations (USD Billion)
Figure 21.17 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
Figure 21.18 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Commercial Operations (USD Billion)
Figure 21.19 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Small Companies (USD Billion)
Figure 21.20 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Mid-sized Companies (USD Billion)
Figure 21.21 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Figure 21.22 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Antibody Therapeutics (USD Billion)
Figure 21.23 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Vaccines (USD Billion)
Figure 21.24 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Cell Therapies (USD Billion)
Figure 21.25 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030 (USD Billion)
Figure 21.26 Biopharmaceutical Contract Manufacturing Market in Italy, 2020-2030 (USD Billion)
Figure 21.27 Biopharmaceutical Contract Manufacturing Market in Germany, 2020-2030 (USD Billion)
Figure 21.28 Biopharmaceutical Contract Manufacturing Market in France, 2020-2030 (USD Billion)
Figure 21.29 Biopharmaceutical Contract Manufacturing Market in Spain, 2020-2030 (USD Billion)
Figure 21.30 Biopharmaceutical Contract Manufacturing Market in the UK, 2020-2030 (USD Billion)
Figure 21.31 Biopharmaceutical Contract Manufacturing Market in Rest of Europe, 2020-2030 (USD Billion)
Figure 21.32 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
Figure 21.33 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
Figure 21.34 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Other Expression System-based Operations (USD Billion)
Figure 21.35 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
Figure 21.36 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Commercial Operations (USD Billion)
Figure 21.37 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Small Companies (USD Billion)
Figure 21.38 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies (USD Billion)
Figure 21.39 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Figure 21.40 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Antibody Therapeutics (USD Billion)
Figure 21.41 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Vaccines (USD Billion)
Figure 21.42 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Cell Therapies (USD Billion)
Figure 21.43 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030 (USD Billion)
Figure 21.44 Biopharmaceutical Contract Manufacturing Market in China, 2020-2030 (USD Billion)
Figure 21.45 Biopharmaceutical Contract Manufacturing Market in India, 2020-2030 (USD Billion)
Figure 21.46 Biopharmaceutical Contract Manufacturing Market in South Korea, 2020-2030 (USD Billion)
Figure 21.47 Biopharmaceutical Contract Manufacturing Market in Japan, 2020-2030 (USD Billion)
Figure 21.48 Biopharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, 2020-2030 (USD Billion)
Figure 21.49 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
Figure 21.50 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
Figure 21.51 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Other Expression System-based Operations (USD Billion)
Figure 21.52 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
Figure 21.53 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Commercial Operations (USD Billion)
Figure 21.54 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Small Companies (USD Billion)
Figure 21.55 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Mid-sized Companies (USD Billion)
Figure 21.56 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Figure 21.57 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Antibody Therapeutics (USD Billion)
Figure 21.58 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Vaccines (USD Billion)
Figure 21.59 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Cell Therapies (USD Billion)
Figure 21.60 Biopharmaceutical Contract Manufacturing Market in Latin America, 2020-2030 (USD Billion)
Figure 21.61 Biopharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2020-2030 (USD Billion)
Figure 22.1 Biopharmaceutical Contract Manufacturing: SWOT Analysis
Figure 22.2 Global Biopharmaceuticals Market: Distribution of Number of FDA Approvals by Year, 2002-2020
Figure 22.3 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 24.1 Survey Analysis: Distribution of Respondents by Company Type
Figure 24.2 Survey Analysis: Distribution of Respondents by Location of Headquarters
Figure 24.3 Survey Analysis: Distribution of Respondents by Designation
Figure 24.4 Survey Analysis: Distribution by Biologics Manufacturing Expertise
Figure 24.5 Survey Analysis: Distribution by Scale of Manufacturing
Figure 24.6 Survey Analysis: Distribution by Location of Production Facilities
Figure 24.7 Survey Analysis: Distribution by Types of Expression Systems Used
Figure 24.8 Survey Analysis: Distribution by Types of Bioreactors
Figure 24.9 Survey Analysis: Distribution by Mode of Operation of Bioreactors

List Of Tables

Table 3.1 Mammalian versus Microbial Expression Systems
Table 4.1 List of Biopharmaceutical CMOs
Table 4.2 Biopharmaceutical CMOs: Information on Type of Product
Table 4.3 Biopharmaceutical CMOs: Information on Types of Biologics Manufactured
Table 4.4 Biopharmaceutical CMOs: Information on Scale of Operation,
Table 4.5 Biopharmaceutical CMOs: Information on Types of Expression Systems Used,
Table 4.6 Biopharmaceutical CMOs: Information on Types of Bioreactors,
Table 4.7 Biopharmaceutical CMOs: Information on Mode of Operation of Bioreactors,
Table 5.1 List of Biopharmaceutical Contract Manufacturing Facilities in North America
Table 5.2 List of Biopharmaceutical Contract Manufacturing Facilities in Europe
Table 5.3 List of Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific
Table 6.1 AGC Biologics: Company Overview
Table 6.2 AGC Biologics: Biologics Manufacturing Facilities
Table 6.3 AGC Biologics: Partnerships
Table 6.4 AGC Biologics: Recent Expansions
Table 6.6 Catalent: Company Overview
Table 6.7 Catalent: Biologics Manufacturing Facilities
Table 6.8 Catalent: Partnerships
Table 6.9 Catalent: Recent Expansions
Table 6.11 Cytiva: Company Overview
Table 6.12 Cytiva: Manufacturing Facilities
Table 6.13 Cytiva: Partnerships
Table 6.14 Cytiva: Recent Expansions
Table 6.16 FUJIFILM Diosynth Biotechnologies: Company Overview
Table 6.17 FUJIFILM Diosynth Biotechnologies: Biopharmaceutical Facilities
Table 6.18 FUJIFILM Diosynth Biotechnologies: Partnerships
Table 6.19 FUJIFILM Diosynth Biotechnologies: Recent Expansions
Table 6.21 KBI Biopharma: Company Overview
Table 6.22 KBI Biopharma: Overview of Manufacturing Capabilities
Table 6.23 KBI Biopharma: List of Partnerships
Table 6.25 Patheon: Company Overview
Table 6.26 Patheon: Biopharmaceutical Manufacturing and Development Facilities
Table 6.27 Patheon: Partnerships
Table 6.28 Patheon: Recent Expansions
Table 6.30 Piramal Pharma Solutions: Company Overview
Table 6.31 Piramal Pharma Solutions: Facilities
Table 7.1 FDA Quality Agreement and EMA cGMP Regulations: A Comparative Analysis
Table 7.2 Boehringer Ingelheim: Company Overview
Table 7.3 Boehringer Ingelheim: Biopharmaceutical Facilities
Table 7.4 Boehringer Ingelheim: Partnerships
Table 7.5 Boehringer Ingelheim: Recent Expansions
Table 7.7 Lonza: Company Overview
Table 7.8 Lonza: Biopharmaceutical Facilities
Table 7.9 Lonza: Partnerships
Table 7.10 Lonza: Recent Expansions
Table 7.12 Novasep: Company Overview
Table 7.13 Novasep: Biologics Manufacturing Facilities
Table 7.14 Novasep: Partnerships
Table 7.15 Novasep: Recent Expansions
Table 7.17 Olon: Company Overview
Table 7.18 Olon: Biopharmaceutical Facilities
Table 7.20 Rentschler Biopharma: Company Overview
Table 7.21 Rentschler Biopharma: Partnerships
Table 7.22 Rentschler Biopharma: Recent Expansions
Table 7.24 Sandoz: Company Overview
Table 8.1 WuXi AppTec (WuXi Biologics): Company Overview
Table 8.2 WuXi Biologics: Partnerships
Table 8.3 WuXi Biologics: Recent Expansions
Table 8.4 WuXi Biologics: Future Outlook
Table 8.5 Kemwell Biopharma: Company Overview
Table 8.6 Kemwell Biopharma: Partnerships
Table 8.7 Kemwell Biopharma: Recent Expansions
Table 8.8 Minaris Regenerative Medicine: Company Overview
Table 8.9 Minaris Regenerative Medicine: Manufacturing Facilities
Table 8.10 Minaris Regenerative Medicine: Partnerships
Table 8.11 Minaris Regenerative Medicine: Future Outlook
Table 8.12 Takara Bio: Company Overview
Table 8.13 Takara Bio: Biologics Manufacturing Facilities
Table 8.14 Takara Bio: Future Outlook
Table 8.15 Celltrion: Company Overview
Table 8.16 Celltrion: Biologics Manufacturing Facilities
Table 8.17 Celltrion: Future Outlook
Table 8.18 Samsung BioLogics: Company Overview
Table 8.19 Samsung BioLogics: Biopharmaceutical Facilities
Table 8.20 Samsung BioLogics: Partnerships
Table 8.21 Samsung BioLogics: Recent Expansions
Table 8.22 Samsung BioLogics: Future Outlook
Table 8.23 Cell Therapies: Company Overview
Table 8.24 Cell Therapies: Partnerships
Table 8.25 Cell Therapies: Future Outlook
Table 8.26 Luina Bio: Company Overview
Table 8.27 Luina Bio: Partnerships
Table 8.28 LuinaBio: Recent Expansions
Table 8.29 Luina Bio: Future Outlook
Table 9.1 Bispecific Antibody Therapeutics: Information on Developer(s), Platform / Technology Used, Phase of Development, Target Antigen and Antibody Format,
Table 9.2 Bispecific Antibody Therapeutics: Information on Developer(s), Technology used, Phase of Development, Target Antigens, Mechanism of Action, Disease Indication, Therapeutic Area and Broader Disease Segment
Table 9.3 List of Other Emerging Multivalent Drug Candidates
Table 9.4 Bispecific Antibody Therapeutics: List of Technology Platforms,
Table 9.5 List of Bispecific Antibody CMOs: Information on Company Specifications
Table 9.6 Commonly Used Cytotoxins for ADC Therapeutics
Table 9.7 Occupational Exposure Limit Bands, Safebridge Consultants
Table 9.8 ADC Therapeutics: Approved / Clinical Pipeline
Table 9.8 Novel Drug Conjugates
Table 9.10 ADC Contract Manufacturing Service Providers: List of Companies
Table 9.11 Application of Cell-based Therapies
Table 9.12 Cell-based Therapies: Commercialized Products,
Table 9.13 Assessments for Key Cell Therapy Manufacturing Steps
Table 9.14 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 9.15 Cell Therapy Contract Manufacturers: Type of Cell Therapy
Table 9.16 List of Cell Therapy Contract Manufacturers
Table 9.17 Viral Vectors Manufacturers: Information on Type of Viral Vector Used
Table 9.18 Viral Vectors: List of Manufacturers
Table 9.19 Plasmid DNA: List of Manufacturers
Table 10.1 Biosimilars Pipeline Analysis: Distribution by Drug Class, 2013 and 2020
Table 10.2 Biosimilar Pipeline Analysis: Distribution by Reference Products, 2013 and 2020
Table 10.3 List of Biosimilars Contract Manufacturing Service Providers
Table 11.1 Small Molecules and Large Molecules: Strengths and Weaknesses
Table 11.2 Small Molecules and Large Molecules: Comparison of Key Characteristics
Table 11.3 Small Molecules and Large Molecules: Comparison of Development Characteristics
Table 12.1 List of FDA Approved Biologics (2016-2020)
Table 14.1 Big Pharma Players: List of Biopharmaceutical Manufacturing Initiatives
Table 15.1 Biopharmaceutical Contract Manufacturing: List of Collaborations, 2015 – 2020
Table 15.2 Biopharmaceutical Contract Manufacturing Partnerships and Collaborations: Information on Types of Biologics Manufactured,
Table 16.1 Biopharmaceutical Contract Manufacturing: List of Mergers and Acquisitions, 2015 - 2020
Table 16.2 Biopharmaceutical Contract Manufacturing Mergers and Acquisitions: Information on Key Value Drivers and Type of Biologics, 2015- 2020
Table 16.3 Mergers and Acquisitions: Deal Multiples, 2015- 2020
Table 17.1 Biopharmaceutical Contract Manufacturing: List of Expansions
Table 18.1 Biopharmaceutical CMOs: Funding Instances
Table 19.1 Capacity Analysis: Information on Contract Biomanufacturing Capacity
Table 19.2 Capacity Analysis: Average Capacity per Category
Table 19.3 Capacity Analysis: Average Capacity for Mammalian Expression Systems
Table 19.4 Capacity Analysis: Average Capacity for Microbial Expression Systems
Table 19.5 Capacity Analysis: Global Contract Biomanufacturing Capacity
Table 20.1 Annual Biomanufacturing Capacity, 2019-2024 (Million Liters)
Table 20.2 ADC Therapeutics: Annual Demand for Outsourcing, 2020-2030 (in kg)
Table 20.3 ADC Therapeutics: Annual Supply for Outsourcing, 2018-2030 (in Kilograms)
Table 22.1 Global Biopharmaceuticals Market: Patent Approval and Expiry Details of Best-selling Biologics
Table 24.1 Survey Analysis: Overview of Respondents
Table 24.2 Survey Analysis: Distribution of Respondents by Designation
Table 24.3 Survey Analysis: Biologics Manufacturing Expertise
Table 24.4 Survey Analysis: Scale of Manufacturing
Table 24.5 Survey Analysis: Location of Production Facilities
Table 24.6 Survey Analysis: Types of Expression Systems Used
Table 24.7 Survey Analysis: Types of Bioreactors
Table 24.8 Survey Analysis: Mode of Operation of Bioreactors
Table 26.1 Biopharmaceutical CMOs: Distribution by Year of Establishment
Table 26.2 Biopharmaceutical CMOs: Distribution by Company Size
Table 26.3 Biopharmaceutical CMO: Distribution by Location of Headquarters (Region-wise)
Table 26.4 Biopharmaceutical CMO: Distribution by Location of Headquarters (Country-wise)
Table 26.5 Biopharmaceutical CMOs: Distribution by Type of Product
Table 26.6 Biopharmaceutical CMOs: Distribution by Types of Biologics Manufactured
Table 26.7 Biopharmaceutical CMOs: Distribution by Types of Biologics Manufactured and Location of Headquarters
Table 26.8 Biopharmaceutical CMOs: Distribution by Types of Biologics Manufactured and Company Size
Table 26.9 Biopharmaceutical CMOs: Distribution by Scale of Operation
Table 26.10 Biopharmaceutical CMOs: Distribution by Types of Biologics Manufactured and Scale of Operation
Table 26.11 Biopharmaceutical CMOs: Distribution by Types of Expression Systems Used
Table 26.12 Biopharmaceutical CMOs: Distribution by Types of Expression Systems Used and Location of Headquarters
Table 26.13 Biopharmaceutical CMOs: Distribution by Types of Bioreactors
Table 26.14 Biopharmaceutical CMOs: Distribution by Mode of Operation of Bioreactor
Table 26.15 Distribution of Biopharmaceutical Contract Manufacturers by Location of Manufacturing Facilities
Table 26.16 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Type of Product
Table 26.17 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Scale of Operation
Table 26.18 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Types of Expression Systems Used
Table 26.19 AGC Biologics: Annual Revenues (JPY Billion)
Table 26.20 Catalent: Annual Revenues (USD Million)
Table 26.21 Cytiva: Annual Revenues (USD Million)
Table 26.22 FUJIFILM Diosynth Biotechnologies: Annual Revenues (JPY Billion)
Table 26.23 FUJIFILM Holdings: Annual Revenues by Business Divisions (JPY Billion)
Table 26.24 Patheon: Annual Revenues (USD Million)
Table 26.25 Piramal Enterprises: Annual Revenues (INR Billion)
Table 26.26 Boehringer Ingelheim: Annual Revenues (EUR Billion)
Table 26.27 Lonza: Annual Revenues (CHF Billion)
Table 26.28 Lonza: Annual Revenues by Business Divisions (CHF Billion)
Table 26.29 Novasep: Annual Revenues (EUR Million)
Table 26.30 Sandoz: Annual Revenues (USD Million)
Table 26.31 Wuxi Biologics: Annual Revenues (RMB Million)
Table 26.32 Celltrion: Annual Revenues (KRW Billion)
Table 26.33 Samsung Biologics: Annual Revenues from CMO Operations (KRW Billion)
Table 26.34 Bispecific Antibody Therapeutics Pipeline: Distribution by Phase of Development
Table 26.35 Bispecific Antibody Therapeutics Pipeline: Distribution by Target Indication
Table 26.36 ADCs Clinical Pipeline: Distribution by Phase of Development
Table 26.37 ADCs Clinical and Commercial Pipeline: Distribution by Target Indication
Table 26.38 ADCs Clinical and Commercial Pipeline: Distribution by Key Technology Providers
Table 26.39 Stem Cell Therapies: Distribution by Phase of Development
Table 26.40 T-Cell Therapies: Distribution by Phase of Development
Table 26.41 Gene Therapies Pipeline: Distribution by Stage of Development
Table 26.42 Gene Therapies Pipeline: Distribution by Phase of Development
Table 26.43 Gene Therapies Clinical and Commercial Pipeline: Distribution by Type of Vector Used
Table 26.44 Gene Therapies Preclinical Pipeline: Distribution by Type of Vector Used
Table 26.45 Gene Therapies Clinical and Commercial Pipeline: Distribution by Target Indication
Table 26.46 Gene Therapies Preclinical Pipeline: Distribution by Target Indication
Table 26.47 Viral Vector Manufacturers: Distribution by Location of Manufacturing Facility
Table 26.48 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
Table 26.49 Pipeline Analysis of Biosimilars, 2013 versus 2020
Table 26.50 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval, 2005-2020
Table 26.51 Approved Biologics: Distribution by Company Size and Type of Manufacturing Model Adopted
Table 26.52 Approved Biologics: Distribution by Company Size and Types of Biologics Manufactured
Table 26.53 Big Pharma Players: Distribution by Number of Biopharmaceutical Contract Manufacturing Focused Initiatives, 1980-2020
Table 26.54 Big Pharma Players: Cumulative Distribution by Year of Initiative
Table 26.55 Big Pharma Players: Distribution by Purpose of Initiative
Table 26.56 Big Pharma Players: Distribution by Type of Initiative
Table 26.57 Big Pharma Players: Distribution by Type of Partnership
Table 26.58 Big Pharma Players: Distribution by Type of Expansion
Table 26.59 Big Pharma Players: Distribution by Scale of Operation
Table 26.60 Big Pharma Players: Distribution by Types of Biologics Manufactured
Table 26.61 Big Pharma Players: Distribution by Purpose of Initiative and Company
Table 26.62 Big Pharma Players: Distribution by Year and Type of Initiative
Table 26.63 Big Pharma Players: Distribution by Region of Expansion and Company
Table 26.64 Partnerships and Collaborations: Distribution by Year of Partnership
Table 26.65 Partnerships and Collaborations: Distribution by Type of Partnership Model Adopted
Table 26.66 Partnerships and Collaborations: Distribution by Focus Area
Table 26.67 Partnerships and Collaborations: Distribution by Focus Area and Type of Partnership Model
Table 26.68 Partnerships and Collaborations: Distribution by Year and Type of Partnership Model Adopted
Table 26.69 Partnerships and Collaborations: Distribution by Types of Biologics Manufactured
Table 26.70 Partnerships and Collaborations: Distribution by Year of Partnership and Types of Biologics Manufactured
Table 26.71 Partnerships and Collaborations: Distribution by Types of Biologics Manufactured and Type of Partnership Model Adopted
Table 26.72 Partnerships and Collaborations: Distribution of Manufacturing Agreements by Types of Biologics Manufactured and Geography
Table 26.73 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 26.74 Partnerships and Collaborations: Most Active Players
Table 26.75 Partnerships and Collaborations: Distribution by Most Active Players and Type of Partnership
Table 26.76 Partnerships and Collaborations: Distribution by Geographical Location (Local and International Agreements)
Table 26.77 Mergers and Acquisitions: Year-Wise Cumulative Trend (2015- 2020)
Table 26.78 Mergers and Acquisitions: Distribution by Type of Acquisition
Table 26.79 Mergers and Acquisitions: Distribution by Region (Continent-wise)
Table 26.80 Mergers and Acquisitions: Distribution by Region (Country-wise)
Table 26.81 Most Active Acquirers: Distribution by Number of Acquisitions
Table 26.82 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 26.83 Mergers and Acquisitions: Distribution by Key Value Drivers and Year of Acquisition
Table 26.84 Mergers and Acquisitions: Distribution by Types of Biologics Manufactured
Table 26.85 Mergers and Acquisitions: Deal Multiples Based on Revenue
Table 26.86 Mergers and Acquisitions: Deal Multiples Based on Revenue
Table 26.87 Facility Expansions: Cumulative Year-wise Trend, 2016-2020
Table 26.88 Facility Expansions: Distribution by Purpose of Expansion
Table 26.89 Facility Expansions: Distribution by Year of Expansion and Purpose of Expansion
Table 26.90 Facility Expansions: Distribution by Types of Biologics Manufactured
Table 26.91 Facility Expansions: Distribution by Types of Biologics Manufactured and Purpose of Expansion
Table 26.92 Facility Expansions: Distribution by Location of Manufacturing Facility (Region-wise)
Table 26.93 Facility Expansions: Distribution by Location of Manufacturing Facility (Country-wise)
Table 26.94 Facility Expansions: Most Active Players
Table 26.95 Facility Expansions: Distribution by Location of Headquarters and Purpose of Expansion
Table 26.96 Capacity Analysis: Distribution by Company Size
Table 26.97 Capacity Analysis: Global Contract Biomanufacturing Capacity based on Types of Expression Systems Used
Table 26.98 Capacity Analysis: Global Contract Biomanufacturing Capacity based on Scale of Operation
Table 26.99 Capacity Analysis: Regional Distribution of Biopharmaceutical CMOs
Table 26.100 Demand Analysis: Annual Demand for Biopharmaceutical Manufacturing, 2020-2030 (in kg)
Table 26.101 Demand Analysis: Distribution of Annual Demand by Therapeutic Area
Table 26.102 Demand Analysis: Annual Demand for ADC Therapeutics (in kg), 2020-2030
Table 26.103 Global Demand for Cell Therapies, 2019-2030 (Number of Patients)
Table 26.104 Global Demand for Cell Therapies, 2019-2030 (Billion Cells)
Table 26.105 Global Biopharmaceutical Contract Manufacturing Market, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.106 Biopharmaceutical Contract Manufacturing Market for API Manufacturing, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.107 Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.108 Biopharmaceutical Contract Manufacturing Market for Others, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.109 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Types of Expression Systems Used (USD Billion)
Table 26.110 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation (USD Billion)
Table 26.111 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Company Size USD Billion)
Table 26.112 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Types of Biologics Manufactured (USD Billion)
Table 26.113 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Geography (USD Billion)
Table 26.114 Biopharmaceutical Contract Manufacturing Market in North America: 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.115 Biopharmaceutical Contract Manufacturing Market in the US, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.116 Biopharmaceutical Contract Manufacturing Market in Canada, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.117 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Mammalian Cell-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.118 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Microbial Cell-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.119 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Other Expression System-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.120 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.121 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Commercial Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.122 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Small Companies, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.123 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Mid-sized Companies, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.124 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.125 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Antibody Therapeutics, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.126 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Vaccines, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.127 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Cell Therapies, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.128 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 26.129 Biopharmaceutical Contract Manufacturing Market in Italy, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.130 Biopharmaceutical Contract Manufacturing Market in Germany, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.131 Biopharmaceutical Contract Manufacturing Market in France, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.132 Biopharmaceutical Contract Manufacturing Market in Spain, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.133 Biopharmaceutical Contract Manufacturing Market in the UK, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.134 Biopharmaceutical Contract Manufacturing Market in Rest of Europe, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.135 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Mammalian Cell-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.136 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Microbial Cell-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.137 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Other Expression System-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.138 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.139 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Commercial Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.140 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Small Companies, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.141 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.142 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.143 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Antibody Therapeutics, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.144 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Vaccines, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.145 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Cell Therapies, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.146 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific: 2020-2030, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.147 Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.148 Biopharmaceutical Contract Manufacturing Market in India, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.149 Biopharmaceutical Contract Manufacturing Market in South Korea, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.150 Biopharmaceutical Contract Manufacturing Market in Japan, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.151 Biopharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.152 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Mammalian Cell-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.153 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Microbial Cell-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.154 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Other Expression System-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.155 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Preclinical / Clinical Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.156 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Commercial Operations, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.157 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Small Companies, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.158 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Mid-sized Companies, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.159 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Large / Very Large Companies, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.160 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Antibody Therapeutics, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.161 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Vaccines, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.162 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Cell Therapies, Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.163 Biopharmaceutical Contract Manufacturing Market in Latin America, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.164 Biopharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
Table 26.165 Global Biopharmaceuticals Market: Number of FDA Approvals by Year, 2002-2020
Table 26.166 Survey Analysis: Distribution of Respondents by Company Type
Table 26.167 Survey Analysis: Distribution of Respondents by Location of Headquarters
Table 26.168 Survey Analysis: Distribution of Respondents by Designation
Table 26.169 Survey Analysis: Distribution by Biologics Manufacturing Expertise
Table 26.170 Survey Analysis: Distribution by Scale of Manufacturing
Table 26.171 Survey Analysis: Distribution by Location of Production Facilities
Table 26.172 Survey Analysis: Distribution by Types of Expression Systems Used
Table 26.173 Survey Analysis: Distribution by Types of Bioreactors
Table 26.174 Survey Analysis: Distribution by Mode of Operation of Bioreactors

List Of Companies

  1. 3P Biopharmaceuticals
  2. 3SBio
  3. 53 Biologics
  4. A.R. BROWN
  5. Aalto Scientific
  6. Labyrinth BioPharma (Formely known as AB BioTechnologies)
  7. AbbVie Contract Manufacturing
  8. AbCellera Biologics
  9. Abeona Therapeutics
  10. ABL
  11. ABL Bio
  12. Abzena
  13. Acasti Pharma 
  14. Accellta
  15. ACES Pharma
  16. Achilles Therapeutics 
  17. Acticor Biotech 
  18. Adagene
  19. Adaptimmune
  20. AdaptVac 
  21. ADC Bio
  22. Adimmune
  23. Advanced Biotherapeutics Consulting
  24. Advanced Cell Technology 
  25. Advanced Scientifics (Acquired by Thermo Fisher Scientific)
  26. Advanced Therapy Treatment Centre (ATTC)
  27. Advaxis
  28. Advent Bioservices 
  29. Aeras 
  30. Affibody
  31. Affinita Biotech
  32. Affinity Life Sciences
  33. Affymetrix
  34. Afton Scientific
  35. AGC Biologics
  36. Agilis Biotherapeutics
  37. Agilux Laboratories
  38. Airway Therapeutics
  39. Ajinomoto Althea
  40. Ajinomoto Bio-Pharma Services
  41. Ajinomoto OmniChem
  42. Akorn
  43. Akouos 
  44. Akron Biotech
  45. Akshaya Bio
  46. Alcami
  47. Aldevron
  48. Alexion
  49. Allele Biotechnology & Pharmaceuticals
  50. Allevi 
  51. Alliance Protein Laboratories APL (Acquired by KBI Biopharma)
  52. Alligator Bioscience
  53. Almac Group
  54. Altor BioScience
  55. Amaran Biotechnology
  56. Amatsigroup (Acquired by Eurofins)
  57. AmbioPharm
  58. American Peptide Company (Acquired by Bachem)
  59. Amgen
  60. Andes Biotechnologies
  61. Antabio
  62. Anthos Therapeutics
  63. apceth Biopharma
  64. Aptevo Therapeutics
  65. Aravive 
  66. Arch Biopartners
  67. Arcturus Therapeutics
  68. Arcus Biosciences
  69. Arecor 
  70. argenx
  71. Ash Stevens
  72. ASLAN Pharmaceuticals
  73. Asterias Biotherapeutics
  74. AstraZeneca
  75. Asymchem
  76. Asymptote (Acquired by GE Healthcare)
  77. Athersys
  78. Austrianova
  79. AutekBio
  80. Autolus
  81. Avecia (acquired by Nitto Denko)
  82. Avid Bioservices
  83. Avrio Biopharmaceuticals
  84. Axcellerate Pharma
  85. Axovant Sciences
  86. Babraham Bioscience Technologies
  87. Baccinex 
  88. Bachem
  89. Batavia Biosciences
  90. Battelle
  91. Baxter BioPharma Solutions
  92. Baylor College of Medicine
  93. Baylor Institute for Immunology Research 
  94. Baylor Scott & White Research Institute (BSWRI)
  95. BCN Peptides 
  96. BDI biotech
  97. Beam Therapeutics 
  98. BeiGene
  99. Beijing Kawin Bio-Tech
  100.  Berkeley Lights
  101.  Bexion Pharmaceuticals 
  102.  Bioindustry Association (BIA) BIA Separations
  103.  BIBITEC
  104.  Bill & Melinda Gates Foundation
  105.  BINEX
  106.  Bio Elpida
  107.  Bioasis
  108.  BioCell 
  109.  BioConnection
  110.  Bio-Ess Laboratories
  111.  Biofabri
  112.  Bio Farma
  113.  Bioinova 
  114.  BioInvent
  115.  Biological E.
  116.  BioMARC
  117.  Biomay
  118.  BioMeca
  119.  Biomedical Advanced Research and Development Authority (BARDA)
  120.  Biomeva (Acquired by AGC Biologics)
  121.  BiondVax Pharmaceuticals
  122.  Bionova Scientific
  123.  BioNTech
  124.  Biopolis Lifesciences
  125.  BiosanaPharma
  126.  BioSig Technologies
  127.  Biospring Partners
  128.  Bio-Synergy 
  129.  Bio-Synthesis
  130.  BioTechnique
  131.  Biotechpharma 
  132.  BioVectra
  133.  Bioverativ
  134.  Biovian
  135.  Bioworkshops
  136.  BioXcellence
  137.  Bliss Biopharmaceutical
  138.  Blue Stream Laboratories
  139.  bluebird bio
  140.  Boehringer Ingelheim
  141.  Boston Children’s Hospital
  142.  BPL Biologics
  143.  Brammer Bio
  144.  Bristol Myers Squibb
  145.  Bryllan
  146.  BSP Pharmaceuticals
  147.  Burrard Pharmaceuticals
  148.  C3i Solutions
  149.  Plasma Industries Belgium (Formely known as CAF-DCF)
  150.  Caisson Biotech
  151.  Calviri
  152.  Calypso Biotech
  153.  Cambridge Pharmaceuticals
  154.  CANbridge
  155.  Cancer Research Technology
  156.  Canton Biologics
  157.  Capsugel
  158.  Capua BioServices
  159.  CARBOGEN AMCIS
  160.  Catalent Biologics
  161.  Catalyst Biosciences
  162.  CDR-Life
  163.  Cell and Gene Therapy Catapult
  164.  Cell Culture Company
  165.  Cell Medica
  166.  Cell Therapies 
  167.  Celladon 
  168.  Cellectis
  169.  CEllforCure 
  170.  CellGenix
  171.  Cellin Technologies
  172.  Celltrion
  173.  Cellular Biomedicine Group
  174.  Cellular Therapeutics
  175.  Celonic
  176.  Celsis (Acquired by Charles River Laboratories)
  177.  Cenexi
  178.  Centaur Biopharmaceutical
  179.  Center for Molecular Medicine Cologne (CMMC)
  180.  Centers for Disease Control and Prevention (CDC)
  181.  Centre for Process Innovation (CPI)
  182.  Coalition for Epidemic Preparedness Innovations (CEPI)
  183.  Commercial & External Partnership, Industrial Affairs (CEPiA)
  184.  Cerbios-Pharma
  185.  Cerium Pharmaceuticals
  186.  CEVEC Pharmaceuticals 
  187.  Charles River
  188.  ChemPartner
  189.  Chime Biologics
  190.  China Regenerative Medicine International (CRMI)
  191.  Chinese Peptide 
  192.  Chiome Bioscience
  193.  CiMaas
  194.  CiRA Foundation 
  195.  Citryll
  196.  California Milk Advisory Board (CMAB)
  197.  CMC Biologics
  198.  CMIC
  199.  Cobra Biologics (Acquired by Cognate BioServices)
  200.  Cochin Shipyard (CSL)
  201.  Cognate BioServices
  202.  Coherus BioSciences
  203.  Coldstream Laboratories
  204.  Columbia University
  205.  CombiGene
  206.  Contract Manufacturing and Development 
  207.  Cook MyoSite
  208.  CordenPharma
  209.  Coretherapix (Acquired by TiGenix)
  210.  CPC Scientific
  211.  CRC for Cell Therapy Manufacturing Cooperative Research Center (CTM CRC)
  212.  Creative Biolabs
  213.  CRISPR Therapeutics
  214.  Cryoport
  215.  CSBio
  216.  CureCell
  217.  Cynata Therapeutics
  218.  Cytiva
  219.  CytoDyn
  220.  CytoSen Therapeutics (Acquired by Kiadis)
  221.  Cytovance Biologics (Acquired by Hepalink USA)
  222.  CyTuVax
  223.  Daiichi Sankyo
  224.  Dalton Partners
  225.  Dalton Pharma Services (Acquired by Seikagaku)
  226.  DanDrit Biotech
  227.  DaTaMabs
  228.  DCPrime
  229.  Denali Therapeutics 
  230.  Dendreon
  231.  US Department of Defense
  232.  DiNAQOR 
  233.  Disposable-Lab (Acquired by Amatsi)
  234.  DM Bio
  235.  Drugs for Neglected Diseases Initiative (DNDi)Downing
  236.  Dyadic International
  237.  Dyax (Acquired by Shire)
  238.  Educell
  239.  EirGenix
  240.  Eisai
  241.  Elion Labs (Acquired by KBI)
  242.  Emergent BioSolutions
  243.  Emerson
  244.  European Regional Development Fund (EDRF)
  245.  Enleofen Bio 
  246.  Enzene
  247.  Epitopoietic Research (ERC)
  248.  Esco Aster
  249.  Etinpro (Beijing)
  250.  EuBiologics
  251.  Eucodis Bioscience
  252.  EUFETS
  253.  Eurofins Scientific
  254.  Eurogentec 
  255.  Euticals
  256.  EVER Pharma
  257.  ExCellThera
  258.  Exelead
  259.  Exelixis 
  260.  FairJourney Biologics
  261.  Faron Pharmaceuticals
  262.  Federal Ministry of Education and Research (BMBF)
  263.  FinVector
  264.  FloDesign Sonics
  265.  Florida Biologix
  266.  For‐Robin
  267.  Forty Seven
  268.  Forum for Innovative Regenerative Medicine (FIRM) 
  269.  Fred Hutchinson Cancer Research Center
  270.  Frederick National Laboratory 
  271.  Freeline
  272.  FUJIFILM Diosynth Biotechnologies
  273.  Fusion Antibodies
  274.  Gadea Pharmaceutical (Acquired by AMRI) 
  275.  Gallant Custom Laboratories 
  276.  GC Cell (Previously known as Green Cross Cell)
  277.  GE Healthcare
  278.  GeneCure Biotechnologies
  279.  GeneDesign
  280.  Genentech
  281.  Geneos Therapeutics
  282.  GeneScience Pharmaceuticals (Acquired by Changchun Hi-Tech Technology)
  283.  Gene-to-Proteins (GTP) Technology
  284.  GenIbet
  285.  Genome 
  286.  Genopis
  287.  Genprex
  288.  German Center for Infection Research (DZIF)
  289.  GigaGen
  290.  Gilead Sciences
  291.  GlycoSeLect 
  292.  Glycotope
  293.  Goodwin Biotechnology
  294.  Government of Canada
  295.  Government of Europe
  296.  Department for Business Energy and Industrial Strategy (BEIS)
  297.  GP Pharm
  298.  Grand River Aseptic Manufacturing (Acquired by Arlington Capital Partners)
  299.  Green Cross LabCell
  300.  GreenPak Biotech
  301.  Greffex
  302.  Grenoble Alpes University Hospital Griffith University
  303.  GlaxoSmithKline (GSK)
  304.  GTP Technology
  305.  Gubra
  306.  HIG Capital
  307.  HALIX
  308.  Hansa Biopharma 
  309.  Harbin Hou pu Tong tang Biotechnology 
  310.  Harbour BioMed
  311.  Harpoon Therapeutics
  312.  Heidelberg Pharma
  313.  Hemogenyx Pharmaceuticals
  314.  Hepalink USA
  315.  Histocell (Acquired by Noray)
  316.  Minaris Regenerative Medicine (Previously known as Hitachi Chemical Advanced          Therapeutics Solutions (HCATS)
  317.  Hong Kong Institute of Biotechnology
  318.  Hookipa Biotech
  319.  Horizon Therapeutics
  320.  Hospira (Acquired by Pfizer)
  321.  Houston Methodist
  322.  Humanigen
  323.  Hummingbird Bioscience
  324.  Hybio Pharmaceutical
  325.  Hycult Biotech
  326.  Hygeia Health
  327.  International AIDS Vaccine Initiative (IAVI) 
  328.  IBC Generium
  329.  IBI Lorenzini
  330.  Icagen
  331.  Ichnos Sciences
  332.  ID Pharma
  333.  IDT Biologika
  334.  I-Mab
  335.  Immune Pharmaceuticals
  336.  ImmunoCellular Therapeutics
  337.  Immunocore
  338.  ImmunoGenesis
  339.  ImmunoTek Bio Centers 
  340.  Imperial Innovations
  341.  In3Bio
  342.  IncoCell Tianjin (A subsidiary of Boyalife)
  343.  Indapta Therapeutics
  344.  Industrial Strategy Challenge Fund (ISCF)
  345.  Inhibrx
  346.  Inno Biologics
  347.  Innovate UK
  348.  Innovation Network Corporation of Japan (INCJ)
  349.  Inovio Pharmaceuticals
  350.  Israel Institute for Biological Research (IIBR)
  351.  Institute for Research
  352.  INSERM-ANRS
  353.  Integrated DNA Technologies (IDT)
  354.  Integrity Biosolution (Acquired by Symyx Technologies)
  355.  IntellectiveBio
  356.  International Consortium of Investigative Journalists (ICIJ)
  357.  International Finance Corporation (IFC)
  358.  Intervacc
  359.  Invetech
  360.  Iovance Biotherapeutics
  361.  IQVIA
  362.  Irvine Scientific 
  363.  IsoPlexis
  364.  Istituto Biochimico Italiano Giovanni Lorenzini
  365.  IVERIC bio
  366.  Janssen Pharmaceuticals
  367.  Japan Tissue Engineering
  368.  Japanese Society for Regenerative Medicine
  369.  JHL Biotech
  370.  Jiangsu Hengrui Medicine
  371.  Jianyi Biotechnology 
  372.  Jitsubo (Acquired by Sosei)
  373.  Johns Hopkins University School of Medicine
  374.  Johnson & Johnson
  375.  JOINN Biologics
  376.  JSR 
  377.  Jubilant HollisterStier
  378.  Juniper Pharmaceuticals
  379.  Juno Therapeutics
  380.  Junshi Biosciences
  381.  Just - Evotec Biologics
  382.  KABS Pharmaceutical Services 
  383.  Kamat Pharmatech
  384.  Kanaph Therapeutics
  385.  Kanda BioTech
  386.  Kaneka Eurogentec
  387.  KBI Biopharma
  388.  Kemwell BioPharma
  389.  Kiadis Pharma
  390.  Kite Pharma
  391.  Kodiak Sciences
  392.  KriSan Biotech
  393.  KUBio
  394.  LamKap Bio
  395.  LAMPIRE Biological Laboratories
  396.  Lava Therapeutics
  397.  Leanbio
  398.  LEUKOCARE
  399.  Levena Biopharma
  400.  LFB Biomanufacturing
  401.  LNC Therapeutics
  402.  Lonza
  403.  LSNE Contract Manufacturing
  404.  LucasPye BIO
  405.  Luina Bio (Previously known as PharmaSynth)
  406.  Lyophilization Technology
  407.  Lyophilization Services of New England (LSNE)
  408.  Lysogene
  409.  MabPlex
  410.  MAbSilico
  411.  Mab-Venture Biopharma
  412.  MacroGenics
  413.  Maine Biotechnology (Acquired by BBI )
  414.  Massachusetts Eye and Ear 
  415.  MassBiologics
  416.  MaSTherCell
  417.  Matica Biotechnology
  418.  Maven Capital Partners
  419.  Medeor Therapeutics
  420.  Medigene
  421.  MedImmune
  422.  MEDINET
  423.  Medisuns
  424.  Medix Biochemica
  425.  MEMO Therapeutics
  426.  Menarini Biotech
  427.  Merck
  428.  Merck Millipore
  429.  Meridian Life Science
  430.  Mesoblast
  431.  MicroBiopharm Japan
  432.  MicrofluidX
  433.  Mila’s Miracle Foundation
  434.  Milner Therapeutics Institute
  435.  Minneapolis Medical Research  Foundation (MMRF)
  436.  Mitsubishi Gas Chemical
  437.  Mitsubishi Tanabe Pharma
  438.  Moderna
  439.  Molecular Partners
  440.  MolMed (Acquired by AGC Biologics)
  441.  Morphotek
  442.  Merck Sharp & Dohme (MSD)
  443.  MTI-GlobalStem (Acquired by Thermo Fisher Scientific)
  444.  Multispan
  445.  Mycenax
  446.  Najít Technologies
  447.  Naobios
  448.  National Cancer Institute
  449.  National Center for Advancing Translational Sciences (NCATS)
  450.  National Heart, Lung, and Blood Institute (NHLBI)
  451.  National Institute of Allergy and Infectious Disease (NIAID)
  452.  Nature Technology
  453.  Navrogen
  454.  Neovacs
  455.  NeoVentures Biotechnology
  456.  Neuland Health Sciences 
  457.  NeuroFx
  458.  Neuway Pharma
  459.  Nikon CeLL innovation
  460.  Nitto Avecia Pharma Services
  461.  Nitto Denko Avecia
  462.  Northway BiotechPharma
  463.  Nouscom
  464.  Novartis
  465.  Novasep
  466.  Novavax
  467.  Novex Innovations
  468.  Numab Therapeutics
  469.  NYU Langone Health
  470.  OBI Pharma
  471.  Octane Biotech
  472.  Ocugen
  473.  Odylia
  474.  Ology Bioservices
  475.  Olon
  476.  Omeros
  477.  Omnia Biologics
  478.  OncoQuest
  479.  OncoVent
  480.  Ondek
  481.  Ono Pharmaceutical
  482.  Orchard
  483.  Orgenesis
  484.  ORPEGEN Peptide Chemicals 
  485.  Osaka University 
  486.  OSE Immunotherapeutics
  487.  OsoBio (Acquired by AMRI)
  488.  Otsuka Pharmaceutical
  489.  Oxford Biomedica
  490.  Oxford Genetics
  491.  Oxford MEStar 
  492.  PacificGMP (Acquired by Abzena)
  493.  PaizaBio
  494.  Pall Corporation
  495.  Panacea Biotec
  496.  PanCELLa
  497.  Panolos Bioscience
  498.  Paragon Bioservices
  499.  Parker Institute for Cancer Immunotherapy
  500.  Particle Sciences
  501.  PATH
  502.  Patheon (Acquired by Thermo Fisher Scientific)
  503.  PaxVax
  504.  PCI Pharma Services
  505.  PCT
  506.  Pfizer
  507.  Pfizer CentreOne
  508.  Phanes Therapeutics
  509.  Pharma Bio
  510.  PharmaCell
  511.  Pharmedartis
  512.  Pharmicell
  513.  PHion Therapeutics
  514.  Pierre Fabre
  515.  Pionyr Immunotherapeutics
  516.  Piramal Pharma Solutions
  517.  PlasmidFactory
  518.  Polaris Pharmaceuticals
  519.  Polpharma Biologics
  520.  Polymun Scientific
  521.  PolyPeptide 
  522.  Portola Pharmaceuticals
  523.  Porton Biopharma
  524.  Praxis Pharmaceutical
  525.  Precision Antibody
  526.  Precision NanoSystems
  527.  Prevail Therapeutics
  528.  Immutep (Formely Known as Prima BioMed) 
  529.  PrimaPharma
  530.  Vivoryon Therapeutics (Formely known as Probiodrug)
  531.  ProBioGen (Acquired by Minapharm Pharmaceuticals)
  532.  Profectus BioSciences
  533.  Prometic Life Sciences
  534.  Propanc Biopharma
  535.  Proteon Therapeutics
  536.  Provia Labs
  537.  PTC Therapeutics 
  538.  PX'Therapeutics
  539.  Q-Biologicals (Acquired by Amatsigroup)
  540.  Radimmune Therapeutics
  541.  Refana
  542.  REGENXBIO
  543.  Regulus Therapeutics
  544.  Relief Therapeutics
  545.  ReNeuron
  546.  Rentschler Biopharma
  547.  Rentschler Biotechnologie
  548.  Rentschler Fill solutions
  549.  RevaTis
  550.  Rexgenero
  551.  Richter-Helm BioLogics
  552.  Ridgeway Biologicals
  553.  River Vision Development
  554.  Roche
  555.  Rocket Pharmaceuticals 
  556.  Roslin Cell Therapies
  557.  Ruibo Bio-Technology
  558.  Saiba 
  559.  Sam Chun Dang Pharm
  560.  Samsung BioLogics
  561.  SanBio
  562.  Sandoz
  563.  Sanofi
  564.  Sanofi-Aventis
  565.  Sanpower 
  566.  Santen Pharmaceutical
  567.  Sarepta Therapeutics
  568.  Sartorius Stedim Biotech 
  569.  Scancell
  570.  Scientific Protein Laboratories (Acquired by Shenzhen Hepalink Pharmaceutical)
  571.  ScinoPharm
  572.  Selecta Biosciences
  573.  Seneca Partners
  574.  Senn Chemicals
  575.  Serendex Pharmaceuticals (Acquired by Savara Pharmaceuticals)
  576.  Serum Institute of India
  577.  Servier
  578.  Shanghai Jiao Tong University
  579.  Sheba Medical Center 
  580.  Shengnuo Peptide
  581.  Shenzhen JYMed Technology
  582.  Shenzhen Watsin Genetech 
  583.  Shire (acquired by Takeda)
  584.  Showa Denko 
  585.  Siam Bioscience 
  586.  Siegfried
  587.  SillaJen
  588.  Singota Solutions
  589.  SIRION Biotech
  590.  Sistemic
  591.  Sonnet BioTherapeutics 
  592.  Spicona
  593.  ST Pharm
  594.  Stanford University School of Medicine
  595.  STCube
  596.  Stelis BioSource
  597.  Stemmatters
  598.  Stratophase
  599.  Sumagen
  600.  Sumitomo Dainippon Pharma
  601.  Sun Pharma
  602.  Surface Oncology 
  603.  Surrozen
  604.  Symbiosis Pharmaceutical Services
  605.  Symphogen
  606.  Wacker Biotech (Formely known as Wacker)
  607.  Synklino
  608.  Synpromics
  609.  Synthace
  610.  Synthelis
  611.  Takara Bio
  612.  Taron Solutions
  613.  TCR2 Therapeutics
  614.  Tectron 
  615.  Telix Pharmaceuticals
  616.  Terumo BCT
  617.  The Chemistry Research Solution (TCRS)
  618.  Development Bank of Wales
  619.  John Hopkins University
  620.  The Michael J. Fox Foundation
  621.  The Native Antigen Company
  622.  Theracell Advanced Biotechnology
  623.  Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI)
  624.  University of Manchester
  625.  Therapure Biopharma (Acquired by Resilience Biotechnologies)
  626.  Theravectys
  627.  Thermo Fisher Scientific
  628.  Thousand Oaks Biopharmaceuticals
  629.  TIEN (Tianjin) Pharmaceutical
  630.  TiGenix
  631.  Tillotts Pharma
  632.  Tizona Therapeutics
  633.  T-knife
  634.  Tmunity Therapeutics
  635.  Tonix Pharmaceuticals
  636.  Toyobo
  637.  TRACON Pharmaceuticals
  638.  TrakCel
  639.  Transgene
  640.  Translate Bio
  641.  Transporin
  642.  TranXenoGen
  643.  Trefoil Therapeutics 
  644.  Trellis Bioscience
  645.  TRIANNI
  646.  Trieza Therapeutics
  647.  Trio Pharmaceuticals
  648.  Triphase Accelerator
  649.  Tsinghua University Innovation Center for Immunotherapy 
  650.  TUBE Biopharmaceuticals
  651.  TxCell (Acquired by Sangamo Therapeutics)
  652.  U.S. Department of Defense
  653.  U.S. Government 
  654.  UGA Biopharma
  655.  UK Cystic Fibrosis Gene Therapy Consortium (GTC)
  656.  UK Government
  657.  Ultragenyx Pharmaceutical
  658.  University College London (UCL)
  659.  University of Aberdeen
  660.  University of Birmingham 
  661.  University of California
  662.  University of Illinois
  663.  University of Leeds
  664.  University of Pennsylvania
  665.  University of Queensland
  666.  University of Sheffield
  667.  University of Tokyo 
  668.  STUNS Life Science
  669.  Vaccines Manufacturing and Innovation Centre (VMIC)
  670.  Vaccitech 
  671.  Valerius Biopharma
  672.  Valneva 
  673.  Vaxart
  674.  VBi Therapeutics
  675.  VBI Vaccines
  676.  Vectron Biosolutions
  677.  Vetter Pharma
  678.  VGXI
  679.  Vibalogics
  680.  VIDO-InterVac
  681.  Vigene Biosciences
  682.  Vineti
  683.  Virovek
  684.  Viscofan
  685.  Voyager Therapeutics
  686.  Vipassana Research Institute (VRI) 
  687.  VTT Technical Research Centre of Finland 
  688.  Wacker Biotech
  689.  Waisman Biomanufacturing
  690.  West Biotherapy
  691.  WIL Research
  692.  Wistar Institute
  693.  WuXi AppTec
  694.  WuXi Biologics
  695.  Wuxi Griffin
  696.  Xbrane Biopharma
  697.  Xellbiogene
  698.  XL-protein 
  699.  Xpress Biologics
  700.  Yposkesi
  701.  Yuhan
  702.  Zealand Pharma 
  703.  Zelluna Immunotherapy
  704.  Zhejiang Hisun Pharmaceutical
  705.  Zhejiang Teruisi Pharmaceutical
  706.  Zhittya Genesis Medicine 
  707.  Ziopharm Oncology
  708.  Zumutor Biologics
  709.  Zymeworks

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com